🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆
Updated 14 Sep 2026 · EMA CTIS official data

EU Clinical Trials Tracker

The most recently authorised clinical trials across the European Union - drawn live from the European Medicines Agency's Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation. Searchable by country, phase, sponsor and condition.

600
Recent authorisations
172
Phase III trials
27
Member states
Showing 600 trials
Phase II Neoplasms Authorised 11/09/2026

COLIBRI-GI_Randomized phase 2 study of second-line chemotherapy comparing FOLFIRI + ivonescimab versus FOLFIRI + bevacizumab in Microsatellite Stable (MSS)/ proficient MisMatch Repair (pMMR) BRAF wild type (wt) advanced colorectal cancer (mCRC) without liver metastases

Patients with non resectable pMMR/MSS BRAF wt mCRC, without liver metastasis in the secondline setting after first-line FOLFOX-based chemotherapy
Unicancer
130 participants planned
France
2025-524215-36-00 on CTIS ↗
Phase IV Neoplasms Authorised 11/09/2026

A Rollover Study to Follow the Long-term Durability of Response to UGN-103 in Participants From Study BL013

Non-Muscle Invasive Bladder Cancer
Urogen Pharma Ltd.
13 participants planned
Latvia
2026-526359-75-00 on CTIS ↗
Phase II Therapeutics Authorised 11/09/2026

Attenuating Calciprotein particles Transformation and Inhibiting Vascular calcification Evolution by Sodium ThioSulphate trial

Vascular Calcification
Radboud universitair medisch centrum Stichting
40 participants planned
Netherlands
2026-525680-41-00 on CTIS ↗
Phase I Diagnosis Authorised 10/09/2026

Targeting fibrotic tissue with a radioactive-labelled Fibrobody, visible using a full-body PET/CT scan (FibroVision)

Bone Morphogenic Protein Receptor type 2 mutation carriers Chronic Kidney Disease Idiopathic Pulmonary Fibrosis Metabolic dysfunction-associated Steatotic Liver Disease Pulmonary Arterial Hypertension Primary Sclerosing Cholangitis
Amsterdam UMC Stichting
57 participants planned
Netherlands
2025-521143-20-00 on CTIS ↗
Phase I Immune System Diseases Authorised 10/09/2026

A Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or ABBV-519 in Subjects with Moderate to Severe Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), or Sjögren's Disease (SjD)

Systemic lupus erythematosus, sjögren's disease and rheumatoid arthritis
AbbVie Deutschland GmbH & Co. KG
20 participants planned
Germany
2026-526282-25-00 on CTIS ↗
Phase I Physiological processes Authorised 10/09/2026

Evaluation of the bioequivalence of two intravaginal gel preparations containing 90 mg progesterone

No therapeutic indication in the current trial with healthy volunteers.
CCDRD Cooperative Clinical Drug Research and Development AG, Ioulia And Irene Tseti Pharmaceutical Laboratories S.A.
48 participants planned
Bulgaria
2025-520498-38-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 10/09/2026

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis
Enveda Therapeutics Inc.
12 participants planned
Germany
2026-526184-38-00 on CTIS ↗
Phase III Reproductive and Urinary Physiological Phenomena Authorised 10/09/2026

SCARP-DIAL (SGLT2i for CARdiovascular Protection in DIALysis)

Chronic dialysis, Cardiovascular disease
Karolinska University Hospital
1000 participants planned
Sweden
2026-526075-35-00 on CTIS ↗
Phase I Neoplasms Authorised 09/09/2026

A PHASE I FIRST-IN-HUMAN, OPEN-LABEL, MULTICENTER STUDYTO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF SIM0505 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS

Advanced solid tumors
Nextcure Inc.
50 participants planned
Italy · France
2026-525888-40-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 09/09/2026

AIRITY: A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma

Asthma
Sanofi-Aventis Recherche & Developpement
346 participants planned
France · Germany
2025-524916-13-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 09/09/2026

C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6)

Overweight or Obesity
Pfizer Inc.
120 participants planned
Spain · Germany · Italy
2026-525318-75-00 on CTIS ↗
Phase II Neoplasms Authorised 09/09/2026

Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high

TMB-high advanced neoplasms
UZ Brussel
40 participants planned
Belgium
2026-525445-73-00 on CTIS ↗
Phase I Skin and Connective Tissue Diseases Authorised 09/09/2026

GRT-2U101: A randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-002 in healthy volunteers and patients with chronic spontaneous urticaria after single or multiple intravenous or subcutaneous dosing of GRT-002 (BASALT trial).

Chronic Spontaneous Urticaria
Granite Bio AG
73 participants planned
Germany
2026-526293-16-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 09/09/2026

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Semaglutide Subcutaneous Depot (CAM2056) in People with Obesity or Overweight

Body weight management
Camurus AB
150 participants planned
Germany
2026-526951-79-00 on CTIS ↗
Phase II Immune System Diseases Authorised 09/09/2026

A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

Uncontrolled Moderate to Severe Eosinophilic Asthma
Kymera Therapeutics Inc.
33 participants planned
Germany · Italy · Slovakia · Spain
2026-526241-98-00 on CTIS ↗
Phase IV Immune System Diseases Authorised 08/09/2026

Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy _ POG

Elderly patients (>70 years old) presenting with cancer and treated with oral therapy in cohorts: • Breast cohort: Abemaciclib, Ribociclib, Palbociclib, Everolimus • Lung cohort: Alectinib, Brigatinib, Osimertinib • Prostate cohort: Abiraterone, Enzalutamide, Olaparib • Colon Cohort: Trifluridine+Tipiracil, Capecitabine • Kidney cohort: Axitinib, Cabozantinib, Lenvatinib • Sarcoma/ GIST cohort: Sunitinib, Regorafenib, Pazopanib
Institut Gustave Roussy
794 participants planned
France
2025-523610-83-00 on CTIS ↗
Phase I Diagnosis Authorised 08/09/2026

A study of IDE892 as monotherapy and combination in MTAP-deleted Advanced Solid Tumors

MTAP-Deleted Advanced Solid Tumors
Ideaya Biosciences Inc.
73 participants planned
Spain · France
2025-524715-37-00 on CTIS ↗
Phase I Hemic and Lymphatic Diseases Authorised 08/09/2026

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Follicular Lymphoma
Eli Lilly & Co.
154 participants planned
Spain · Italy · France · Germany
2025-523601-16-00 on CTIS ↗
Phase III Neoplasms Authorised 08/09/2026

A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315)

Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy
Amgen Inc.
100 participants planned
Netherlands · Hungary · Portugal · France · Belgium · Italy · Spain
2026-525489-23-00 on CTIS ↗
Phase IV Hormonal diseases Authorised 08/09/2026

A double-blind, randomised, 30-week placebo-controlled phase IV study to assess the efficacy and safety of osilodrostat in patients with hypertension caused by hypercortisolaemia due to Cushing’s Syndrome

Cushing's syndrome
Recordati AG
51 participants planned
Germany · France · Italy
2025-524649-28-00 on CTIS ↗
Phase I/II Immune System Diseases Authorised 08/09/2026

A Phase Ia/II Randomized Controlled Trial of Daratumumab Alone Versus Daratumumab Plus Abatacept for resistant active Antibody-Mediated Rejection in Kidney Transplant Recipients

active Antibody-Mediated Rejection in Kidney Transplant Recipients
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
20 participants planned
Spain
2026-526730-73-00 on CTIS ↗
Phase III Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 08/09/2026

A Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1

Gaucher Disease Type 1
Spur Therapeutics Limited
4 participants planned
Spain
2025-520765-50-00 on CTIS ↗
Phase I Neoplasms Authorised 08/09/2026

A clinical trial to learn about the effects of 225Ac-ETN029 in people with advanced solid tumors

Small Cell Lung Cancer (SCLC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Large Cell Neuroendocrine Carcinoma (LCNEC) of the lung
Novartis Pharma AG
37 participants planned
France · Spain · Italy · Germany
2024-519111-34-00 on CTIS ↗
Phase II Immune System Diseases Authorised 08/09/2026

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy

Sjogren’s Disease-Associated Sensorimotor Polyneuropathy (SMPN) or Sensory Polyneuropathy (SPN)
Argenx
37 participants planned
Germany · Lithuania · Portugal · Slovakia · Hungary · Spain · Austria · Belgium · France
2026-526218-10-00 on CTIS ↗
Phase III Immune System Diseases Authorised 08/09/2026

EFC18362 - A Phase 3, multicenter, multinational, randomized, open-label, active-comparator study to evaluate the efficacy and safety of venglustat compared with Cerezyme in pediatric participants 2 to 11 years of age with Gaucher disease type 3 who have reached therapeutic goals with enzyme replacement therapy

Immune system diseases
Sanofi-Aventis Recherche & Developpement
9 participants planned
Hungary · Italy · France · Finland · Germany
2026-525374-19-00 on CTIS ↗
Phase IV Anesthesia and Analgesia Authorised 08/09/2026

POISON – Perioperative Safety and Effective Opioid Dosing in Chronic Opioid Use – a Randomized Clinical Study

Opioid dependent chronic pain
Region Hovedstaden
318 participants planned
Denmark
2026-526719-13-00 on CTIS ↗
Phase II Male Urogenital Diseases Authorised 08/09/2026

SemenGlutide: A randomized double-blinded, placebo-controlled, single-center, clinical trial comparing the effects of s.c. Semaglutide 2.4 mg once-weekly versus placebo on sperm concentration in overweight infertile men

Infertility, overweight
Region Hovedstaden
150 participants planned
Denmark
2026-527538-29-00 on CTIS ↗
Phase II Hormonal diseases Authorised 08/09/2026

Effects of semaglutide as add-on therapy to sulfonylurea on plasma glucose in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SEMA)

Maturity-onset diabetes of the young type 3 (HNF1A-MODY), Maturity-onset diabetes of the young type 1 (HNF4A-MODY)
Steno Diabetes Center Copenhagen
54 participants planned
Denmark
2025-523414-89-00 on CTIS ↗
Phase IV Virus Diseases Authorised 07/09/2026

A Phase IV, open label, single arm trial to assess the safety and immunogenicity of BIMERVAX® XFG.1.1 against SARS-CoV-2 Omicron XFG.1.1 variant.

COVID-19
Hipra Scientific S.L.
70 participants planned
Spain
2026-527363-16-00 on CTIS ↗
Phase II Neoplasms Authorised 07/09/2026

A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as First-line Treatment for Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb Services Unlimited Company
29 participants planned
Italy · Germany
2026-525170-19-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 07/09/2026

A research study looking into how a high dose of s.c. semaglutide works with emptying of the stomach in people with excess body weight

Participants with obesity
Novo Nordisk A/S
60 participants planned
Austria
2026-526083-20-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 07/09/2026

"Evaluation of the impact of the dose of heparin on the occurrence of DWI ischemic lesions after embolization of unruptured intracranial aneurysm" "HARMONI"

Intracranial aneurysms
Centre Hospitalier Universitaire De Bordeaux
124 participants planned
France
2026-526530-13-00 on CTIS ↗
Phase I/II Immune System Diseases Authorised 07/09/2026

A Long-Term Follow-Up Study to Assess the Safety and Efficacy of B-Cell-Directed Therapy in Patients with Systemic Autoimmune Disease (B-CARE)

systemic autoimmune diseases
Universitaetsklinikum Erlangen AöR
150 participants planned
Germany
2026-526888-37-00 on CTIS ↗
Phase I Immune System Diseases Authorised 07/09/2026

A trial to learn how safe anifrolumab is, how it moves throughout the body over time, and how it affects the body of adults with systemic lupus erythematosus

Systemic Lupus Erythematosus
AstraZeneca AB
1 participants planned
Hungary
2026-526171-32-00 on CTIS ↗
Phase III Neoplasms Authorised 07/09/2026

Zoledronic acid as prophylaxis against glucocorticoid-induced osteoporosis in lymphoma

Large B-cell lymphomas, transformations of indolent B-cell lymphomas, mantle cell lymphoma, follicular lymphoma, Burkitt lymphoma and T-cell lymphomas (The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms), Glucocorticoid induced osteoporosis
Region Nordjylland
132 participants planned
Denmark
2026-527220-27-00 on CTIS ↗
Phase I Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 07/09/2026

A Study to Learn How Different Manufactured Products of the Study Medicine Called Osivelotor (PF-07940367) Taste and Are Taken Up Into the Blood When Mixed With Soft Foods or Liquids Given on an Empty Stomach or Given With Food or an Acid Reducing Agent in Healthy Adults

Sickle Cell Disease
Pfizer Inc.
52 participants planned
Belgium
2024-511410-20-01 on CTIS ↗
Phase II Nervous System Diseases Authorised 07/09/2026

Phase 2, randomized, blinded, non-treatment-controlled study assessing the efficacy and safety of dimethyl fumarate in patients with NBIA, a neurodegeneration associated with brain iron accumulation.

Neurodegeneration with brain iron accumulation (NBIA), including pantothenate kinase-associated neurodegeneration (PKAN) and mitochondrial membrane protein-associated neurodegeneration (MPAN).
Instytut Psychiatrii I Neurologii
40 participants planned
Poland
2026-525990-38-00 on CTIS ↗
Phase I Immune System Diseases Authorised 07/09/2026

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

Rheumatoid arthritis (RA)
Eli Lilly & Co.
15 participants planned
Germany
2025-523980-39-00 on CTIS ↗
Phase I Neoplasms Authorised 07/09/2026

Study of GS-2426 in Participants With Advanced Solid Tumors

MTAP-Deleted Advanced Solid Tumors
Gilead Sciences Inc.
37 participants planned
Spain
2026-526264-20-00 on CTIS ↗
Phase I Neoplasms Authorised 07/09/2026

A Study of RO7806767 as Single Agent and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Advanced Solid Tumors
F. Hoffmann-La Roche AG
99 participants planned
Spain · Hungary · Italy · Belgium · Denmark · France
2026-525215-13-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 07/09/2026

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia

Tardive Dyskinesia
Neurocrine Biosciences Inc.
15 participants planned
Bulgaria · Slovakia · Czechia
2025-524104-30-00 on CTIS ↗
Phase I/II Virus Diseases Authorised 04/09/2026

Phase 1/2, first-in-human, randomized, double-blind, reference-controlled study to evaluate the safety and immunogenicity of an extemporaneously mixed Combo Inactivated Influenza Vaccine (Green Cross [GC]-IIV; 15µg of each hemagglutinin [HA])/OVX836 (480µg), in comparison to GC-IIV (15µg of each HA) concomitantly administered with OVX836 (480µg), GC-IIV alone (15 µg each HA), OVX836 alone (480µg), and a licensed reference trivalent IIV (Vaxigrip®; 15µg of each HA), administered intramuscularly (IM) in healthy participants

Influenza disease
Osivax
250 participants planned
Belgium
2026-526939-19-00 on CTIS ↗
Phase I Metabolism Authorised 04/09/2026

A Phase 1 study of a novel sublingual insulin formulation

Type 1 diabetes mellitus
Sublin B.V.
19 participants planned
Netherlands
2025-521863-11-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 04/09/2026

A Multicenter, Open-Label, Single-Group Clinical Study to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab in Pediatric Subjects (aged 6 to 23 months) with Moderate-to-Severe Atopic Dermatitis Not Adequately Controlled with Topical Therapy

Atopic Dermatitis
Galderma S.A.
30 participants planned
Poland
2025-525027-27-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 04/09/2026

Randomized, Double blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants with Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)

Venous Thromboembolism
Ribocure Pharmaceuticals AB
150 participants planned
Poland · Romania · France · Bulgaria
2026-525479-15-00 on CTIS ↗
Phase I Mental Disorders Authorised 04/09/2026

A Study to See How a New Compound, Trontinemab Affects the Body and Whether Immune Signals Triggered by it Affect How Other Medicines are Processed

Not Applicable
F. Hoffmann-La Roche AG
46 participants planned
Germany
2026-526756-31-00 on CTIS ↗
Phase I Male Urogenital Diseases Authorised 04/09/2026

An Open-Label, Phase 1 Dose-finding Study to Define the Maximum Tolerated Dose and Schedule of TRP-001 as Neoadjuvant Therapy in Treatment-naïve Very High-Risk Prostate Cancer Patients Eligible for Radical Prostatectomy with Extended Pelvic Lymph Node Dissection

Prostate cancer
Torpedo Pharmaceuticals AG
18 participants planned
Germany
2026-526406-32-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 04/09/2026

Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once daily in participants with type 2 diabetes and increased cardiovascular risk inadequately controlled on 1–3 oral glucose-lowering medications (AMBITION 7)

Type 2 diabetes (T2D) and increased cardiovascular (CV) risk not in adequate glycaemic control on 1–3 marketed oral glucose lowering medications.
Novo Nordisk A/S
477 participants planned
Greece · Germany · Italy · Czechia · Poland · Bulgaria · Spain
2026-525209-11-00 on CTIS ↗
Phase I Neoplasms Authorised 03/09/2026

A Phase I dose escalation study of intrapleural administration of Oncofid-P-M in patients with unresectable recurrent/progressive pleural mesothelioma after first-line treatment

unresectable recurrent/progressive pleural mesothelioma
Fidia Farmaceutici S.p.A.
30 participants planned
Italy
2026-526119-12-00 on CTIS ↗
Phase III Neoplasms Authorised 03/09/2026

Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.

Metastatic renal cell carcinoma
Fondazione IRCCS Istituto Nazionale Dei Tumori
500 participants planned
Italy
2025-523903-31-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 02/09/2026

BiFAST : A phase II trial evaluating fixed dose and faster ramp-up of epcoritamab with lenalidomide for 3L relapse/refractory large B-cell lymphoma after CAR T-cells therapy in 2nd line

3L relapse/refractory large B-cell lymphoma after CAR T-cells therapy in 2nd line
LYSARC
55 participants planned
France
2025-520895-24-00 on CTIS ↗
Phase IV Therapeutics Authorised 02/09/2026

ACTOR – AUC Control of Tacrolimus in Organ Recipients

Kidney transplantation
Oslo Universitetssykehus HF
24 participants planned
Norway
2026-527107-22-00 on CTIS ↗
Phase II Neoplasms Authorised 02/09/2026

Hyperthermic Intraperitoneal Chemotherapy and Regional Adrenalectomy in the management of Stage II & III Adrenocortical Carcinoma

Adrenocortical Carcinoma
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
32 participants planned
Italy
2026-525406-36-00 on CTIS ↗
Phase II Behavior and Behavior Mechanisms Authorised 02/09/2026

Propranolol Dosefinding Assessment in Reactive Aggression Treatment (PRO-DART)

Reactive aggression
Radboud universitair medisch centrum Stichting
30 participants planned
Netherlands
2026-526545-95-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 02/09/2026

First-in-human evaluation of [11C]UCB-1A as imaging marker for synaptic vesicle glycoprotein 2C (SV2C): a PET study in healthy volunteers and participants with Parkinson’s disease

Parkinson's disease
Karolinska Institutet
40 participants planned
Sweden
2026-526848-13-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 02/09/2026

Reduced-dose versus full-dose systemic thrombolysis for high-risk pulmonary embolism: a multicentre, randomised, open-label, blinded-endpoint trial

Pulmonary embolism
Vaestra Goetalandsregionen, University Of Gothenburg
280 participants planned
Denmark · Sweden · Norway
2024-515904-37-00 on CTIS ↗
Phase III Immune System Diseases Authorised 02/09/2026

A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy

Immune system diseases
Sanofi-Aventis Recherche & Developpement
338 participants planned
Belgium · Czechia · Hungary · Sweden · Lithuania · Croatia · Netherlands · Slovakia · Poland · Austria · Norway · France · Italy · Bulgaria · Spain · Germany · Romania · Slovenia · Estonia · Portugal · Greece · Denmark
2026-525913-30-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 02/09/2026

A phase III, randomized, prospective, double-blind, parallel design, multi-arm, multicenter study to compare the efficacy and safety of alogliptin and empagliflozin combination therapy versus alogliptin alone and empagliflozin alone in metformin-treated participants with type 2 diabetes mellitus and insufficient glycemic control despite diet and exercise (ODISSEIA 2026).

Type 2 Diabetes mellitus
Tecnimede-Sociedade Tecnico-Medicinal S.A.
760 participants planned
Poland · Germany · Portugal · Italy · Spain
2025-524606-15-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 02/09/2026

Antibiotikapenetration og vævsrespons ved infektion og rekonstruktiv kirurgi i hoved-hals regionen

Treatment and prevention of post operative infections
Region Midtjylland
16 participants planned
Denmark
2026-526995-22-00 on CTIS ↗
Phase I Virus Diseases Authorised 01/09/2026

A randomized, placebo-controlled trial, to evaluate the safety, immunogenicity and the optimal dose of MOPEVAC-Las vaccine candidate against Lassa Fever, in healthy volunteers consisting of an unblinded dose escalation and a blinded treatment phase (FIRST-IN-MOP)

Lassa fever
Institut Pasteur
72 participants planned
France
2025-524034-26-02 on CTIS ↗
Phase I Neoplasms Authorised 01/09/2026

A study to test how well different doses of BI 4060107 are tolerated by people with advanced cancer (solid tumours)

solid tumours
Aimed Bio lnc.
15 participants planned
France
2026-525187-18-00 on CTIS ↗
Phase I Therapeutics Authorised 01/09/2026

PRadR 2 - A single center, open-label, Phase I study evaluating 161Tb-PSMA therapy in adult patients with metastatic clear cell renal cell carcinoma

Metastatic clear cell renal cell carcinoma
Centre Leon Berard
35 participants planned
France
2026-525526-38-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 01/09/2026

Effect of GABAergic treatments on cortical plasticity and motor learning capacity in the subacute phase after stroke: a single-case experimental study (GABAPLAST)

Stroke
Centre Hospitalier Universitaire De Toulouse
12 participants planned
France
2026-526884-39-00 on CTIS ↗
Phase II Neoplasms Authorised 01/09/2026

A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator's choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy (SACICUP)

Neoplasm
Universitaetsklinikum Heidelberg AöR
100 participants planned
Germany
2025-523055-55-00 on CTIS ↗
Phase II Eye Diseases Authorised 01/09/2026

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompe' Farmaceutici S.p.A.
171 participants planned
Denmark · Italy · Germany · Hungary · Netherlands · Spain · Belgium · France · Portugal
2025-524748-37-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 01/09/2026

Randomized, controlled, multi-center trial to evaluate the efficacy, tolerability, and safety of an (S)-ibuprofen gel vs. placebo in the local symptomatic and short-term treatment of pain in acute contusions of the soft tissues following blunt trauma

acute contusions of soft tissues
Aponia Laboratories Inc.
120 participants planned
Germany
2025-524451-31-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 01/09/2026

A multicenter, prospective, randomized, placebo and non-surgical standard of care (NSSOC) controlled study, performed to evaluate the safety and efficacy of EscharEx and its placebo (gel vehicle) compared to NSSOC in participants with Venous Leg Ulcers (VLU)

Venous Leg Ulcer (VLU)
Mediwound Ltd.
35 participants planned
Czechia · Slovakia
2026-526070-16-00 on CTIS ↗
Phase III Neoplasms Authorised 01/09/2026

A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5).

Newly Diagnosed Multiple Myeloma
AstraZeneca AB
234 participants planned
Poland · Italy · Denmark · France · Sweden · Germany · Spain
2025-524014-29-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 01/09/2026

A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of VQ-101 in participants with Parkinson’s disease carrying a heterozygous mutation of GBA1

GBA1-associated Parkinson’s disease
Vanqua Bio Inc.
16 participants planned
Netherlands · France · Spain · Germany
2026-525848-15-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 01/09/2026

Optimization of Dupilumab Maintenance Dosing in Eosinophilic Esophagitis: A Phase IV, Randomized, Controlled, Single-Blind, Non-Inferiority Study

Eosinophilic Esophagitis
Amsterdam UMC Stichting
160 participants planned
Netherlands
2026-526348-11-01 on CTIS ↗
Phase III Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 31/08/2026

A Phase 3, Randomized, Double-blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)

Hereditary Hemorrhagic Telangiectasia (HHT)
Vaderis Therapeutics AG
130 participants planned
Hungary · Netherlands · Germany · Bulgaria · France · Italy · Lithuania · Spain · Belgium
2025-524490-17-00 on CTIS ↗
Phase II Neoplasms Authorised 31/08/2026

Clinical Study of Local and Systemic biological Impact of GLP1/GIP-Receptor Agonists in patients with Breast Cancer: The CLARA trial

Hormone Receptor positive postmenopausal breast cancer
UZ Leuven
168 participants planned
Belgium
2026-525820-76-00 on CTIS ↗
Phase I/II Neoplasms Authorised 31/08/2026

​​Perioperative zanidatamab combined with chemotherapy in HER2-positive locally advanced operable gastroesophageal adenocarcinoma (GEA): a Phase 1b/2a single-arm trial​

Gastroesophageal adenocarcinoma (GEA)
UZ Leuven
29 participants planned
Belgium
2025-523483-20-00 on CTIS ↗
Phase I/II Otorhinolaryngologic Diseases Authorised 31/08/2026

An Open-Label, Multicenter Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of Intracochlear Ascending Dose Injections of SENS-601 Followed by Expansion Cohort in Pediatric Population With Hearing Loss Related to Biallelic Pathogenic Variation(s) of GJB2, As Well As to Demonstrate the Performance of the Administration System, Its Safety, Its Clinical Benefit, and Its Usability.

Hearing Loss Related to biallelic pathogenic variation (s) of the GJB2 Gene.
Sensorion
6 participants planned
France
2026-525698-38-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 31/08/2026

A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of Salanersen (BIIB115) After Onasemnogene Abeparvovec Treatment in Infants with Genetically Diagnosed Spinal Muscular Atrophy

Spinal Muscular Atrophy
Biogen Idec Research Limited
24 participants planned
Portugal · Italy · Belgium · Croatia · Hungary · Germany · Ireland · France · Norway · Poland
2025-523857-32-00 on CTIS ↗
Phase II Neoplasms Authorised 31/08/2026

A Phase II, single-arm trial on the addition of the DLL3xCD3 bispecific T-cell engager obrixtamig (BI 764532) to standard-of-care platinum-based first-line treatment of advanced large-cell neuroendocrine carcinoma of the lung (ALPINE 2)

Male and female adult patients with locally advanced or metastatic large-cell neuroendocrine carcinoma of the lung not eligible for curative treatment
Technische Universitaet Dresden
75 participants planned
Germany
2025-524345-28-00 on CTIS ↗
Phase III Not possible to specify Authorised 31/08/2026

Evaluation of the Impact of a Strategy of Perioperative NSAID Suppression in Patients Undergoing Video-assisted Thoracic Surgery (VATS) on the Presence of Chronic Postoperative Pain (CPOP): a Randomised Clinical Trial (EVADRAINS)

Thoracic surgery
Les Hopitaux Universitaires De Strasbourg
318 participants planned
France
2025-524917-96-00 on CTIS ↗
Phase I Not possible to specify Authorised 31/08/2026

A research study looking at the effect of timing of meal after dosing and water volume at dosing on how the medicine zenagamtide is taken up by the body of participants with overweight or obesity

overweight/obesity
Novo Nordisk A/S
320 participants planned
Germany
2025-521383-35-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 31/08/2026

Targeted versus standard peri-operative prophylaxis in patients colonized with carbapenemase-producing Enterobacterales undergoing liver transplantation: a stepped-wedge cluster randomization trial

Patients colonized with CPE undergoing liver transplantation (LT)
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
168 participants planned
Italy
2025-523453-34-00 on CTIS ↗
Phase II Neoplasms Authorised 31/08/2026

In-vivo fluorescence molecular bronchoscopy of durvalumab-680LT in patients with unresectable stage III NSCLC after chemoradiation - PulmoPrint

Unresectable stage III non-small cell lung cancer
Universitair Medisch Centrum Groningen
20 participants planned
Netherlands
2026-526251-60-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 31/08/2026

HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL)
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
276 participants planned
Czechia · Denmark · Croatia · Spain · Sweden · Finland · Portugal · Ireland · Netherlands · Belgium · Norway
2025-524230-25-00 on CTIS ↗
Phase IV Nervous System Diseases Authorised 31/08/2026

Incidence and severity of postoperative delirium associated with Dexmedetomidine sedation during femur osteosynthesis in the elderly population

Postoperative delirium
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
80 participants planned
Spain
2025-523070-16-00 on CTIS ↗
Phase I Hemic and Lymphatic Diseases Authorised 31/08/2026

REGN9220 in Combination with Odronextamab in Adult Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)

B-cell Non-Hodgkins Lymphoma (B-NHL)
Regeneron Pharmaceuticals Inc.
10 participants planned
Belgium
2025-524780-20-00 on CTIS ↗
Phase II Immune System Diseases Authorised 31/08/2026

Targeting IL-13 in Bullous Pemphigoid: An Investigator-Initiated, Prospective, Multicenter, Proof-of-Concept, Open-Label Pilot Study of Lebrikizumab

Bullous pemphigoid
Region Midtjylland, Region Sjaelland
25 participants planned
Denmark
2026-525685-22-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 31/08/2026

Efficacy and safety of once-weekly subcutaneous UBT251 in participants with type 2 diabetes – a dose-finding study

Type 2 diabetes (T2D)
Novo Nordisk A/S
175 participants planned
Spain · Hungary · Romania · Slovakia · Poland · Germany
2026-525465-42-00 on CTIS ↗
Phase IV Hormonal diseases Authorised 29/08/2026

A prospective, randomized, double-blinded, placebo-controlled, cross-over study investigating the effects of metyrapone treatment on cardio-metabolic outcome parameters and chronobiology in patients with mild autonomous cortisol secretion

Mild autonomous cortisol secretion
Medical University Of Vienna
40 participants planned
Austria
2026-526837-24-00 on CTIS ↗
Phase II Diagnosis Authorised 28/08/2026

Paediatric sarcoma, hybrid imaging & FAPI – Raising the diagnostic standard for paediatric sarcoma patients combining novel radiotracer FAPI and whole-body PET/MRI

Paediatric sarcoma
Rigshospitalet
40 participants planned
Denmark
2025-524874-41-00 on CTIS ↗
Phase III Neoplasms Authorised 28/08/2026

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB COMPARED WITH INVESTIGATOR’S CHOICE OF IMMUNOTHERAPY OR OBSERVATION IN PATIENTS WITH RESECTED STAGE II-III KRAS G12C-POSITIVE NON-SMALL CELL LUNG CANCER

Resected Stage II-III Kirsten rat sarcoma virus oncogene homolog glycine 12 to Cysteine (KRAS G12C) -Positive Non-Small Cell Lung Cancer
F. Hoffmann-La Roche AG
198 participants planned
France · Spain · Austria · Greece · Portugal · Ireland · Belgium · Italy · Germany · Netherlands
2025-524263-21-01 on CTIS ↗
Phase I Male Urogenital Diseases Authorised 28/08/2026

An Open-Label Study of IDE034 in Adult Participants with Locally Advanced/Metastatic Solid Tumors

Locally Advanced/Metastatic Solid Tumors -non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), endometrial cancer, high-grade serous ovarian cancer (HGSOC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), and castration-resistant prostate cancer (CRPC)
Ideaya Biosciences Inc.
15 participants planned
Spain
2026-526299-21-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 28/08/2026

A prospective, exploratory, parallel-group, low-intervention, phase IV, randomized, double-blind, placebo-controlled, multi-center, national, 2-arm trial to investigate efficacy and safety of Amara-Tropfen (Amara drops) in patients with irritable bowel syndrome (IBS)

Irritable Bowel Syndrome
Weleda AG
106 participants planned
Germany
2026-526668-19-00 on CTIS ↗
Phase I/II Neoplasms Authorised 27/08/2026

A Phase 1/2, Open-Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination with other Antileukemic Agents in participants with Selected Myeloid Malignancies

Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome /Acute Myeloid Leukemia (MDS/AML) or Chronic Myelomonocytic Leukemia (CMML)
Institut De Recherches Internationales Servier IRIS
38 participants planned
Netherlands · Spain · Germany · Italy · France · Finland
2025-525128-88-00 on CTIS ↗
Phase IV Pathological Conditions, Signs and Symptoms Authorised 27/08/2026

S-KETamine vs. propofol for prehospital sedation of patients with severe Acute Brain Injury: The KETABI randomised trial

traumatic brain injury, subarachnoid haemorrhage, intracerebral haemorrhage
Region Hovedstaden
284 participants planned
Denmark
2026-525588-41-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 27/08/2026

Relative oral bioavailability and tolerability of hydrocortisone from 2-dimensionally printed orodispersible films in children and adolescents with primary adrenal insufficiency (REPLACE trial)

adrenal insufficiency
Universitaetsklinikum Heidelberg AöR
8 participants planned
Germany
2026-526416-37-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 27/08/2026

A multicenter, open-label, single-arm, baseline-controlled trial to assess the efficacy and safety of lucerastat in treatment-naïve/pseudo-naïve adult male participants with Fabry disease

Fabry disease
Idorsia Pharmaceuticals Ltd.
8 participants planned
Germany · France
2026-525207-27-00 on CTIS ↗
Phase II Mental Disorders Authorised 26/08/2026

MDMA-assisted therapy for adolescents with treatment-resistant PTSD

Post-traumatic stress disorder
Stichting Amsterdam UMC
12 participants planned
Netherlands
2024-515184-65-01 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 26/08/2026

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Contineum Therapeutics Inc.
156 participants planned
Italy · Belgium · Denmark · Austria · Greece · Germany · France · Netherlands · Portugal · Poland · Spain
2025-521901-42-00 on CTIS ↗
Phase II Neoplasms Authorised 26/08/2026

C6461010 - An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-08634404 Monotherapy or in Combination in Adult Participants with Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer

Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer
Pfizer Inc.
33 participants planned
Spain · France · Italy · Ireland · Germany · Poland
2025-524825-42-00 on CTIS ↗
Phase II Neoplasms Authorised 26/08/2026

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

Gastrointestinal Cancers
Genmab A/S
67 participants planned
Italy · Belgium · France · Spain · Denmark · Netherlands · Germany
2025-524130-26-00 on CTIS ↗
Phase II Hormonal diseases Authorised 26/08/2026

Development of a Short-Acting GH Suppression Test with subcutaneous short action Pasireotide (PAT) for Predicting Long-Term Response to Pasireotide LAR in Patients with Acromegaly

Acromegaly
Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol
40 participants planned
Spain
2025-524253-14-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 26/08/2026

A Phase 2a, proof-of-concept, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to assess the efficacy and safety of ACT-777991 in adults with non-segmental vitiligo

Non-segmental vitiligo
Idorsia Pharmaceuticals Ltd.
24 participants planned
Czechia · Poland
2025-524865-25-00 on CTIS ↗
Phase I Not possible to specify Authorised 26/08/2026

Bioequivalence clinical trial of two formulations of empagliflozin/metformin

Healthy volunteers
Laboratorios Normon S.A.
30 participants planned
Spain
2026-527325-35-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 25/08/2026

DIRECTION- Discontinuation versus continuation of riociguat monotherapy in chronic thromboembolic pulmonary hypertension successfully treated with balloon pulmonary angioplasty

chronic thromboembolic pulmonary hypertension
Assistance Publique Hopitaux De Paris
150 participants planned
France
2026-525351-81-00 on CTIS ↗
Phase II Immune system processes Authorised 25/08/2026

A Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression with Tacrolimus, Mycophenolic Acid and Corticosteroids (MODERNIZE 1)

Renal Transplantation
Nefro Avillion Clinical Development LLC
27 participants planned
Czechia · Spain · Portugal · Austria
2026-525646-29-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 25/08/2026

Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial

Acute ischemic stroke
Fondation A De Rothschild
592 participants planned
France
2026-525280-40-00 on CTIS ↗
Phase II Diagnosis Authorised 25/08/2026

[68]GA-FAPI-46 PET/CT for the diagnosis of metastatic lesions in patients with lobular breast cancer (ICL). FAPICL

invasive lobular carcinomas of the breast
Hospices Civils De Lyon
45 participants planned
France
2025-524897-40-00 on CTIS ↗
Phase I Musculoskeletal Diseases Authorised 25/08/2026

A single and multiple ascending dose study of DFL23693 in healthy volunteers

Osteoarthritis
Dompe' Farmaceutici S.p.A.
76 participants planned
France
2026-527078-35-00 on CTIS ↗
Phase I Neoplasms Authorised 25/08/2026

A Phase 1 Study of CTIM-76 in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors

Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors (Testicular and Endometrial Cancer)
Context Therapeutics Inc.
36 participants planned
France · Spain
2025-523968-20-00 on CTIS ↗
Phase III Immune System Diseases Authorised 25/08/2026

A Phase 3, open-label extension study to evaluate the long-term safety and efficacy of rozanolixizumab in adult participants with ocular myasthenia gravis

Ocular Myasthenia Gravis
UCB Biopharma
46 participants planned
Hungary · France · Greece · Poland · Spain · Italy · Germany
2025-524757-14-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 25/08/2026

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Narcolepsy Followed by an Open-label Extension

narcolepsy
Harmony Biosciences Management Inc.
92 participants planned
Belgium · Italy · Germany · France · Spain · Poland
2025-523821-17-00 on CTIS ↗
Phase I Digestive System Diseases Authorised 25/08/2026

A Phase 1 Trial to Evaluate the Safety, PK, and PD of AX-0811 in Healthy Participants

Cholestatic disease
ProQR Therapeutics VIII B.V.
44 participants planned
Belgium
2026-526764-21-00 on CTIS ↗
Phase I Not possible to specify Authorised 25/08/2026

The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used for lowering levels of cholesterol in the blood.

No medical condition
Adamed Pharma S.A.
60 participants planned
Czechia
2026-527468-34-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 25/08/2026

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis (AD)
Apollo Therapeutics Limited
138 participants planned
Hungary · Czechia · Germany · Bulgaria · Poland · Spain
2026-525673-39-00 on CTIS ↗
Phase I Cardiovascular Diseases Authorised 25/08/2026

Bioavailability Comparison of Valsartan 320 mg Tablets (Test vs. Reference Product)

Not applicable (submitted trial is a BE study in healthy participants)
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
34 participants planned
Czechia
2026-527569-31-00 on CTIS ↗
Phase II Neoplasms Authorised 25/08/2026

Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
Janssen Cilag International
123 participants planned
Sweden · Spain · Greece · Portugal · France · Hungary
2025-524793-42-00 on CTIS ↗
Phase II Neoplasms Authorised 25/08/2026

Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent Studies Investigating Adagrasib (BMS-986503)

Solid tumor
Bristol-Myers Squibb Services Unlimited Company
116 participants planned
Greece · Hungary · Poland · Belgium · Spain · Netherlands · Germany · France · Portugal · Italy · Romania
2025-524905-34-00 on CTIS ↗
Phase IV Bacterial Infections and Mycoses Authorised 25/08/2026

Piperacillin/tazobactam or ampicillin and gentamicin for empirical treatment of community acquired infection: A randomised clinical trial (PAGER)

Urosepsis, Infection of unknown origin, Pyelonephritis, Cystitis, Urinary tract infection, Pneumonia, Sepsis
Region Hovedstaden
2162 participants planned
Denmark
2026-526131-20-00 on CTIS ↗
Phase I Neoplasms Authorised 24/08/2026

A Phase 1 Study of TT125-802 as Monotherapy and in Combination with Pomalidomide and Dexamethasone in Participants with Multiple Myeloma

Relapsed and Refractory Multiple Myeloma
TOLREMO therapeutics AG
25 participants planned
Italy · Spain
2025-523536-39-00 on CTIS ↗
Phase I/II Bacterial Infections and Mycoses Authorised 24/08/2026

A combined phase I/IIa trial to investigate the safety and pharmacokinetics of StaphAcute in healthy participants and patients with Staphylococcus aureus bacteremia - StaphAcute

Phase IIa: patients with methicillin susceptible (MSSA) or methicillin resistant (MRSA) Staphylococcus aureus bacteremia (SAB)., Phase I: first in human application in healthy particpants, dose escalation study.
University Of Cologne
54 participants planned
Germany
2024-511586-10-01 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 24/08/2026

Proof of cOncept Study demonStrating the potential substitutIon of suBcutaneous Injection of recombinant human insulin by subLIngual administration of S.L.I.M®-Formulations in TYpe-I DIABEtic PaTiEntS

Patients with diabete type 1 under pump
Sublin B.V.
24 participants planned
France
2025-524539-38-01 on CTIS ↗
Phase III Nervous System Diseases Authorised 24/08/2026

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Etifoxine Monotherapy in The Treatment of Adjustment Disorder with Anxiety (ADWA)

Treatment of adjustment disorder with anxiety (ADWA).
Biocodex
20 participants planned
France
2025-524287-38-00 on CTIS ↗
Phase III Neoplasms Authorised 24/08/2026

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)

Pancreatic Adenocarcinoma
Revolution Medicines Inc.
281 participants planned
Sweden · Spain · France · Poland · Italy · Norway · Belgium · Germany · Czechia · Austria · Netherlands · Denmark
2025-524928-21-00 on CTIS ↗
Phase IV Skin and Connective Tissue Diseases Authorised 24/08/2026

Adalimumab Treatment for Patients with Hidradenitis Suppurativa at high risk of Progressing to Severe Disease: An Unblinded Randomized, Controlled Trial

Hidradenitis suppurativa
Gentofte Hospital
100 participants planned
Denmark
2025-522505-37-00 on CTIS ↗
Phase I/II Cardiovascular Diseases Authorised 24/08/2026

A Prospective Diagnostic Trial of Al[¹⁸F]F-NOTA-folate PET in Patients with Suspected Cardiac Sarcoidosis or Infective Endocarditis and Healthy Volunteers (FOL-CARD)

Cardiac Sarcoidosis, Infective endocarditis
Turku University Hospital
143 participants planned
Finland
2026-526655-59-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 24/08/2026

Evaluation of the efficacy and safety of photodynamic therapy with BF-200 ALA (Ameluz®) in immunosuppressed patients with actinic keratoses and superficial basal cell carcinoma at any location.

Immunosuppressed patients with premalignant and malignant skin lesions, such as actinic keratosis (AK), cutaneous squamous cell carcinoma (cSCC), and basal cell carcinoma (BCC), due to chronic immunosuppression.
Dra. Elena González Guerra
120 participants planned
Spain
2026-526649-85-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 21/08/2026

A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Potential Antiseizure Activity of Adjunctive OV329 Therapy in Adults with Drug-Resistant Focal Epilepsy

Focal epilepsy
Ovid Therapeutics Inc.
6 participants planned
Netherlands
2026-525896-23-00 on CTIS ↗
Phase III Female Urogenital Diseases and Pregnancy Complications Authorised 21/08/2026

FOSFOLD - Fosfomycin trometamol compared with another active antibiotic relay therapy for the treatment of acute Escherichia coli pyelonephritis in elderly women: a randomized, multicenter, non-inferiority trial

Women aged 75 years or older presenting with E. coli pyelonephritis
Assistance Publique Hopitaux De Paris
312 participants planned
France
2025-521663-13-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 21/08/2026

Surgery versus intra-lesional sclerosis with polidocanol (Aetoxisclerol) in labial venous malformations in children and adults: a randomized controlled trial - SASOV

superficial labial venous malformation
Centre Hospitalier Regional Universitaire De Tours
50 participants planned
France
2025-521374-34-00 on CTIS ↗
Phase III Neoplasms Authorised 21/08/2026

A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase III Study to Evaluate the Efficacy and Safety of Letrozole SIE Compared to Femara® (both in Combination with the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women with HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer (SIE-3)

​​HR-positive, HER2-negative, inoperable locally advanced or metastatic breast cancer​
Laboratorios Farmaceuticos Rovi S.A.
97 participants planned
Romania · Spain · Bulgaria · Czechia · Latvia · Poland · Croatia · Slovakia
2025-524846-85-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 21/08/2026

A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera

Polycythemia Vera
Deciphera Pharmaceuticals Inc.
106 participants planned
Austria · Czechia · Italy · Portugal · Germany · France · Hungary · Spain · Poland
2025-524669-25-00 on CTIS ↗
Phase III Neoplasms Authorised 21/08/2026

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

Neoplasms, Gastrointestinal Stromal
Glaxosmithkline Research & Development Limited
302 participants planned
Italy · Portugal · Germany · Sweden · Poland · Romania · Finland · Greece · Norway · Spain · Netherlands · France · Hungary
2025-524934-24-00 on CTIS ↗
Phase III Neoplasms Authorised 21/08/2026

A Multicenter, Randomized, Double-Blind, 2-Treatment Arm Study to Assess Comparative Pharmacokinetics, Efficacy, Safety and Immunogenicity Between Intravenous AVT32-DRL_PB and Keytruda® as an Adjuvant Treatment in Participants with Stage IIB/C-III Melanoma Following Complete Resection

Stage IIB/C-III Melanoma
Alvotech Swiss AG
32 participants planned
Romania · Spain
2025-525093-11-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 21/08/2026

A randomized, double-blind, placebo-controlled clinical trial to investigate the human monoclonal antibody NG004 in acute, incomplete cervical spinal cord injury (SCI) patients

Acute Incomplete Cervical Spinal Cord Injury
NovaGo Therapeutics AG
84 participants planned
Germany
2026-526089-26-00 on CTIS ↗
Phase I/II Neoplasms Authorised 21/08/2026

A multicenter, non-therapeutic, interventional, long-term follow-up clinical trial to evaluate the safety of autologous PRAME-directed TCR T cell therapy IMA203 or IMA203CD8 in patients with previously treated, advanced and/or metastatic solid tumors

Solid tumors
Immatics US Inc.
9 participants planned
Germany
2026-525827-25-00 on CTIS ↗
Phase III Eye Diseases Authorised 21/08/2026

A Randomized, Double-Masked, Placebo-Controlled Study Assessing the Efficacy and Safety Of Privosegtor (OCS-05) as add-on to IV Methylprednisolone in Participants with Optic Neuritis (PIONEER 1)

Optic Neuritis
Oculis Operations SARL
82 participants planned
Italy · Germany · France · Poland · Spain
2025-525075-91-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 21/08/2026

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With α- or β-Non–Transfusion-Dependent Thalassemia (ENERGIZEKids)

Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
Agios Pharmaceuticals Inc.
3 participants planned
Italy · Greece
2025-524706-15-00 on CTIS ↗
Phase II Bacterial Infections and Mycoses Authorised 21/08/2026

Èn dosis intravenøs penicillin som tillæg til peroral penicillin i behandlingen af akut tonsillitis, peritonsillær phlegmone og peritonsillær absces – et randomiseret, dobbeltblindet, placebo-kontrolleret studie

Tonsillitis
Region Midtjylland
154 participants planned
Denmark
2026-526903-31-00 on CTIS ↗
Phase III Neoplasms Authorised 21/08/2026

A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
K-Group Beta Inc.
197 participants planned
Germany · Spain · Italy · Belgium · Poland · France · Ireland
2025-524641-27-00 on CTIS ↗
Phase I Not possible to specify Authorised 21/08/2026

A study to see how safe a new medicine (NNC0705-0002) is in healthy people

Cardiometabolic
Novo Nordisk A/S
112 participants planned
Netherlands
2026-526205-15-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 21/08/2026

A Phase I Study using Oncolytic AdenoVirus Immunotherapy with Repeat Administrations in Recurrent GliOblastoma (VIRAGO)

Recurrent Glioblastoma
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
18 participants planned
Netherlands
2025-524555-31-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 21/08/2026

A Randomized, Double-Blind, Phase 2 Trial Evaluating the Efficacy, Safety and Tolerability of Primary Cardioprotection with Dapagliflozin in Patients with Newly Diagnosed Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Multiple Myeloma
Instytut Hematologii I Transfuzjologii
418 participants planned
Poland
2026-525418-67-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 21/08/2026

A 52-week multicenter, randomized, parallel-group trial in overweight people investigating lifestyle changes, mushroom supplementation and bupropion to reduce adiposity and cardiometabolic risk

Overweight or class I obesity (BMI 25.0–34.9 kg/m²), with or without cardiometabolic risk factors (hypertension, hyperlipidemia, and/or prediabetes).
Uppsala University
250 participants planned
Sweden
2026-527136-13-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 20/08/2026

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With α- or β-Transfusion-Dependent Thalassemia (ENERGIZEKids-T)

Transfusion-Dependent Alpha- or Beta-Thalassemia
Agios Pharmaceuticals Inc.
8 participants planned
Italy · Greece
2025-524707-71-00 on CTIS ↗
Phase III Neoplasms Authorised 20/08/2026

A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants with Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

High Risk Smoldering Multiple Myeloma (HR-SMM)
Regeneron Pharmaceuticals Inc.
108 participants planned
Italy · Spain · Poland · France · Norway · Greece · Germany
2025-523252-31-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 20/08/2026

Multicenter, open-label single arm phase I study evaluating the safety and efficacy of combined MB-CART19.1-IBK cells and the 2nd generation BTK-inhibitor Zanubrutinib in relapsed or refractory PCNSL "Zanubrutinib and CAR T cells in R/R PCNSL: Z-CARP-Study" A prospective non-randomized multicenter phase I study

relapsed/ refractory Primary central nervous system lymphoma (r/r PCNSL)
Medizinische Universitaet Innsbruck
18 participants planned
Germany · Austria
2024-520342-28-00 on CTIS ↗
Phase I Neoplasms Authorised 20/08/2026

Synergism of dendritic cell vaccination and anti-PD-L1 immune check-point blockade to sensitize recurrent glioblastoma to anti-tumoral immunity

Recurrent Glioblastoma
Heinrich-Heine-Universitaet Duesseldorf
6 participants planned
Germany
2026-525397-19-00 on CTIS ↗
Phase III Eye Diseases Authorised 20/08/2026

A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR

Stargardt Disease (STGD1)
Alkeus Pharmaceuticals Inc.
64 participants planned
Belgium · France · Spain · Italy · Germany
2026-525296-60-00 on CTIS ↗
Phase I/II Neoplasms Authorised 20/08/2026

Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA

osteosarcomas, chondrosarcomas, Ewing sarcomas, Ewing-like tumors with rare fusions, CIC-DUX4 bone sarcomas
Les Hopitaux Universitaires De Strasbourg
89 participants planned
France
2026-525463-40-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 20/08/2026

Effects of Menopausal Hormone Therapy on QTc in Genetically Confirmed Long QT Syndrome: A Prospective Randomized Sequential Crossover Study with Long-Term Observational Follow-Up (LQTS-HER)

Long QT syndrome
Oslo Universitetssykehus HF
15 participants planned
Norway
2026-526442-28-00 on CTIS ↗
Phase I/II Neoplasms Authorised 20/08/2026

A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination with Anti-Cancer Agents in Participants with Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours (PARTHENON)

Solid Tumors
AstraZeneca AB
10 participants planned
Spain
2025-524171-22-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 20/08/2026

An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin Amyloidosis
Eidos Therapeutics Inc.
50 participants planned
Spain · Denmark
2026-526068-19-00 on CTIS ↗
Phase III Neoplasms Authorised 20/08/2026

Impact of Hyperthermic Intrathoracic Chemotherapy (HITHOC) and Pleurectomy in the local treatment of pleural tumors. A Prospective Randomized Study The Tic-Tac Trial

malignant pleural effusion
Universita' Degli Studi Di Torino
64 participants planned
Italy
2026-526109-13-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 20/08/2026

J2S-MC-GZMS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants with IBS-D

Irritable Bowel Syndrome Diarrhea
Eli Lilly & Co.
186 participants planned
Germany · Poland · Spain · Belgium
2025-524973-17-00 on CTIS ↗
Phase II Mental Disorders Authorised 19/08/2026

Treatment of post-traumatic stress disorder with medical nitrous oxide combined with exposure to a personal traumatic script: a multicenter randomized controlled trial (POTESTA)

Post-Traumatic Stress Disorder
Centre Hospitalier Regional Universitaire De Tours
96 participants planned
France
2026-525826-39-00 on CTIS ↗
Phase I Virus Diseases Authorised 19/08/2026

A clinical trial of MK-8210 in healthy participants (MK-8210-001)

HIV-1 (Human Immunodeficiency Virus Type 1)
Merck Sharp & Dohme LLC
88 participants planned
Belgium
2026-527022-13-00 on CTIS ↗
Phase III Mental Disorders Authorised 19/08/2026

JS2-MC-GZMI: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse Compared with Placebo in Adult Participants with Major Depressive Disorder (RENEW-MDD- 2)

Depressive Disorder, Major
Eli Lilly & Co.
228 participants planned
Poland · Greece · Spain · Germany
2025-522310-24-00 on CTIS ↗
Phase I Neoplasms Authorised 19/08/2026

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer
Janux Therapeutics Inc.
30 participants planned
Spain
2026-526777-42-00 on CTIS ↗
Phase I/II Neoplasms Authorised 18/08/2026

A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Solid Tumours
Terremoto Biosciences Inc.
228 participants planned
Spain · Ireland · Hungary · Romania · France · Portugal · Belgium · Poland
2025-525036-34-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 18/08/2026

Evaluation of an asPirin-free strategy with ticAgrelor in patieNTs witH a myocardial infarction treatEd medically alONe (PANTHEON)

myocardial infarction
Montreal Heart Institute
600 participants planned
France
2025-525159-20-00 on CTIS ↗
Phase III Immune System Diseases Authorised 18/08/2026

A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rozanolixizumab in adult participants with ocular myasthenia gravis

Ocular Myasthenia Gravis
UCB Biopharma
46 participants planned
Hungary · Greece · Italy · Spain · Germany · Poland · France
2025-524756-54-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 18/08/2026

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial to Evaluate Safety, and Pharmacodynamics of Repeated Subcutaneously Administered RBD1119 in Participants with CAD

Coronary artery disease
Ribocure Pharmaceuticals AB
200 participants planned
Sweden · Poland
2026-525901-10-00 on CTIS ↗
Phase II Neoplasms Authorised 18/08/2026

A Phase II, Randomized, Open-label, Multi-center Study of AK104 in Combination with Lenvatinib versus Lenvatinib in Participants with Advanced Hepatocellular Carcinoma Who Have Progressed on Atezolizumab and Bevacizumab

Hepatocellular Carcinoma
Akeso Biopharma Co. Ltd.
37 participants planned
Poland · France · Spain · Italy
2025-524591-30-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 18/08/2026

A study to test how well different and multiple doses of BI 3034701 are tolerated in people living with overweight or obesity

overweight, obesity
Boehringer Ingelheim International GmbH
35 participants planned
Germany
2026-526090-42-00 on CTIS ↗
Phase I Not possible to specify Authorised 18/08/2026

A clinical research study investigating how the body processes the new compound afabicin in people with kidney problems and people with normal kidney function

Renal Impairment
Debiopharm International S.A.
60 participants planned
Germany
2026-526916-35-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 18/08/2026

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)

Elevated lipoprotein(a)
Merck Sharp & Dohme LLC
295 participants planned
Netherlands · Denmark · Germany · Spain
2025-525102-38-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 18/08/2026

A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week SAR448851 treatment followed by open-label extension in participants with early Alzheimer’s disease.

Dementia Alzheimer's type
Sanofi-Aventis Recherche & Developpement
266 participants planned
Spain · Germany
2025-524581-14-00 on CTIS ↗
Phase III Anesthesia and Analgesia Authorised 17/08/2026

Evaluation of the efficacy of intravenous lidocaine on chronic postoperative pain in patients requiring emergency abdominal surgery. Randomized, double-blind, controlled, multicenter study – LIDOC-POPEYE.

emergency abdominal surgery
Centre Hospitalier Universitaire De Nantes
266 participants planned
France
2025-523682-24-00 on CTIS ↗
Phase II Neoplasms Authorised 17/08/2026

FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML

acute myeloid lymphoma
Institut Paoli Calmettes
77 participants planned
France
2025-523632-39-00 on CTIS ↗
Phase III Eye Diseases Authorised 17/08/2026

A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered via Intravitreal Injection in Participants with Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration (nAMD)
Amgen Inc.
255 participants planned
Slovakia · Latvia · Czechia · Poland · Spain · Hungary · Lithuania
2025-523500-72-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 17/08/2026

Efficacy of rituximab for remission maintenance in patients with primary angiitis of the central nervous system: an open-label, randomized, controlled trial comparing systematic rituximab infusions and azathioprine - MAINRIPAC

Patients with primary angiitis of the central nervous system
Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience
74 participants planned
France
2026-525394-39-00 on CTIS ↗
Phase I Neoplasms Authorised 17/08/2026

A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer

Metastatic castration resistant prostate cancer
Novartis Pharma AG
26 participants planned
France · Italy · Spain · Germany
2025-524080-20-00 on CTIS ↗
Phase III Neoplasms Authorised 17/08/2026

Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)

Small-cell lung cancer, limited stage
Norges Teknisk-Naturvitenskapelige Universitet NTNU
426 participants planned
Denmark · Finland · Estonia · Germany · Lithuania · Sweden · Norway · Netherlands
2026-525513-31-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 17/08/2026

Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on Walking Ability in Patients in the Chronic Phase of Stroke

Stroke
Sinfatin S.L.
80 participants planned
Spain
2025-521693-33-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 17/08/2026

C4931007 - A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Pneumoccoccal Immunisation
Pfizer Inc.
1345 participants planned
Spain · Finland · Poland · Germany · Greece · Hungary · Italy
2025-523447-35-02 on CTIS ↗
Phase I/II Neoplasms Authorised 17/08/2026

A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)

Lymphoma, Non-Hodgkin
Glaxosmithkline Research & Development Limited
30 participants planned
Italy · Germany · Spain · Finland · France
2025-524915-36-00 on CTIS ↗
Phase III Male Urogenital Diseases Authorised 17/08/2026

A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer

Metastatic castration-resistant prostate cancer (mCRPC)
BioNTech SE
183 participants planned
Belgium · Spain · Italy · Poland · Germany · Hungary
2025-524445-27-00 on CTIS ↗
Phase I Respiratory Tract Diseases Authorised 17/08/2026

A Two-part study to learn the amount of polymyxin E1 in the body over time formed after a single inhaled dose of colistimethate sodium (CMS) in healthy adults (Part 1) and after single inhaled and vein-infused doses of CMS in adults with non‑cystic fibrosis bronchiectasis (NCFB) (Part 2)

Non-cystic fibrosis bronchiectasis
Zambon S.p.A.
55 participants planned
Belgium · Poland · Bulgaria
2025-524324-22-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 17/08/2026

A Phase III Randomised, Double-Blind, Parallel-Group Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared with Rosuvastatin on Low-Density Lipoprotein Cholesterol in Patients with Hypercholesterolaemia.

Hypercholesterolaemia
AstraZeneca AB
60 participants planned
Germany
2026-526258-15-00 on CTIS ↗
Phase II Mental Disorders Authorised 14/08/2026

A phase IIa open-label dose-finding study with lead-in phase evaluating the safety, pharmacokinetics, and attenuating effects of trazodone on the consciousness-altering effects of psilocybin in individuals with Treatment-Resistant Depression

Treatment-Resistant Depression
Universita' Degli Studi G. D'Annunzio Di Chieti
30 participants planned
Italy
2025-523346-27-00 on CTIS ↗
Phase III Neoplasms Authorised 14/08/2026

The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI

Advanced hepatocellular carcinoma
Azienda Sanitaria Locale Napoli 1 Centro
1700 participants planned
Italy
2026-525898-39-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 14/08/2026

Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial)

Erosive hand osteoarthritis (EHOA)
Azienda Ospedaliera Universitaria Integrata Verona
150 participants planned
Italy
2026-526828-41-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 14/08/2026

A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)

heart failure
Cardurion Pharmaceuticals Inc.
369 participants planned
Latvia · Slovakia · Lithuania · Hungary · Italy · Netherlands · Spain · Poland · Bulgaria · Czechia
2025-525033-31-00 on CTIS ↗
Phase I Not possible to specify Authorised 14/08/2026

A study to test how BI 3034701 is taken up and processed by the body in healthy men with normal weight or overweight

Healthy
Boehringer Ingelheim International GmbH
8 participants planned
Hungary
2026-525825-19-00 on CTIS ↗
Phase I Female Urogenital Diseases and Pregnancy Complications Authorised 14/08/2026

Bioequivalence of Estradiol 10 mcg Vaginal Tablets in Healthy Women Participants.

Not applicable (submitted trial is a bioavailability trial in healthy participants).
Laboratorios Leon Farma S.A.
48 participants planned
Czechia
2026-526477-42-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 14/08/2026

A Phase 2 Randomized Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients with Severe Asthma not Adequately Controlled with Medium to High Dose ICS/LABA Therapy (PANAIRAMA)

Severe asthma
Kinaset Therapeutics Inc.
350 participants planned
Czechia · Bulgaria · Romania · Hungary · Germany · Poland · Greece
2023-509125-41-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 14/08/2026

An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer’s Disease

Early Alzheimer’s Disease
Merry Life Biomedical Co. Ltd.
70 participants planned
Sweden
2026-525539-18-00 on CTIS ↗
Phase I/II Immune System Diseases Authorised 14/08/2026

An open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseases

ANCA associated vasculitis (AAV), Immune thrombocytopenic purpura (ITP), Multiple sclerosis (MS), Rheumatoid arthritis (RA), Pemphigus vulgaris (PV), Systemic sclerosis (SSc), Inflammatory idiopathic Myositis (IIM)
Universitaetsklinikum Tuebingen AöR
36 participants planned
Germany
2024-519491-60-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 14/08/2026

A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Adults With Previously Untreated Primary Immune Thrombocytopenia (ITP)

Diagnosis of primary ITP according to the 2019 International Consensus Report that is previously untreated and requires treatment
Amgen Inc.
42 participants planned
Spain · Hungary · Germany
2026-525454-11-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 14/08/2026

TIPS : Immunomodulatory Treatment of Interstitial Lung Disease Associated with Surfactant related Gene Mutations

Interstitial Lung Disease
Assistance Publique Hopitaux De Paris
30 participants planned
France
2026-525336-41-00 on CTIS ↗
Phase II Neoplasms Authorised 14/08/2026

[⁶⁸Ga]Ga-HKG301 PET/CT for staging and restaging patients with primary breast cancer: a phase II study (FAPILOUS)

Primary breast cancer
Odense University Hospital
65 participants planned
Denmark
2025-521324-29-00 on CTIS ↗
Phase II Male Urogenital Diseases Authorised 14/08/2026

Quantitative Unified Assessment of Novel Triplet therapy and Unconventional Maintenance with Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard
50 participants planned
Spain
2026-525550-11-00 on CTIS ↗
Phase IV Metabolism Authorised 14/08/2026

Phase IV Low Intervention Clinical Trial to Study Biomarkers of "inflammageing" and Senescence in Pre-diabetic Patients Treated with Metformin: A Study nested within the project “NLRP3 Inflammasome at the Crossroad of Vascular Inflammageing: A Novel Target for Senomorphic Drugs”.

Pre-diabetic Patients
Universidad Autonoma De Madrid
105 participants planned
Spain
2026-527080-15-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 13/08/2026

Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma [FIRE-12]

locally advanced or metastatic small bowel adenocarcinoma
Charite Universitaetsmedizin Berlin KöR
112 participants planned
Germany
2025-524131-39-00 on CTIS ↗
Phase I Neoplasms Authorised 13/08/2026

A Phase 1b Study of ZN-c3 in Combination with Chemotherapy or Bevacizumab in Subjects with Ovarian, Peritoneal, or Fallopian Tube Cancer

Ovarian, Peritoneal, or Fallopian Tube Cancer
K-Group Beta Inc.
40 participants planned
France
2025-524868-38-00 on CTIS ↗
Phase II Bacterial Infections and Mycoses Authorised 13/08/2026

Multicenter, randomized, open-label non-inferiority trial, comparing two antibiotic therapy periods (3 versus 7 days) in patients with mild leptospirosis and seen at the hospital in 5 French overseas departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)

leptospirosis
CHU De Martinique
304 participants planned
France
2024-518027-30-00 on CTIS ↗
Phase II Neoplasms Authorised 13/08/2026

A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)

HR-positive/HER2-negative advanced breast cancer
Medica Scientia Innovation Research S.L.
25 participants planned
Spain · Italy · Germany
2026-525328-10-00 on CTIS ↗
Phase I/II Nutritional and Metabolic Diseases Authorised 13/08/2026

A two-part, randomised, double-blind, placebo-controlled, parallel-group, 12week trial investigating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in obese participants

Obesity
Pila Pharma AB
46 participants planned
Sweden
2026-525869-42-00 on CTIS ↗
Phase III Neoplasms Authorised 13/08/2026

SERAFA-1: A Single arm, Open label, Multicentre, Phase IIIb Study Of Camizestrant plus Ribociclib in 1st line Treatment of ER-positive, HER2-negative Advanced Breast Cancer Patients

Breast Cancer
AstraZeneca AB
79 participants planned
Poland · Spain · France · Germany · Italy
2025-523444-12-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 13/08/2026

A randomized, double blind, placebo-controlled study comparing the efficacy of dupilumab to standard of care (SOC) treatment following hospitalization for a COPD exacerbation

Chronic obstructive pulmonary disease (COPD)
Regeneron Pharmaceuticals Inc.
190 participants planned
Belgium · Italy · Spain
2025-524392-23-00 on CTIS ↗
Phase II Genetic Phenomena Authorised 12/08/2026

AN OPEN LABEL, SINGLE ARM, EXPLORATIVE TRIAL TO EVALUATE EFFICACY AND SAFETY OF BEROTRALSTAT IN PREVENTING ANGIOEDEMA ATTACKS IN SUBJECTS WITH ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE)

Acquired angioedema due to C1 inhibitor deficiency
Policlinico San Donato S.p.A.
16 participants planned
Italy
2025-524747-13-00 on CTIS ↗
Phase III Diagnosis Authorised 12/08/2026

International, multicenter, blinded phase III clinical trial to assess the diagnostic efficacy of the skin prick test from ROXALL (SPT-RX) with different allergen extract solutions for in vivo diagnosis of IgE mediated allergies

Patients suffering from rhinitis / rhinoconjunctivitis, with well-controlled mild-to-moderate asthma or without asthma, due to the exposure to any of the allergen sources under investigation, for at least 2 years in case of seasonal allergenic sources or for at least 1 year in case of perennial allergenic sources.
ROXALL Medizin GmbH
140 participants planned
Germany · Spain
2025-524676-32-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 12/08/2026

A RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL OF COLCHICINE IN AMYOTROPHIC LATERAL SCLEROSIS (CO-ALS II)

AMYOTROPHIC LATERAL SCLEROSIS
Azienda Ospedaliero Universitaria Di Modena
87 participants planned
Italy
2026-526460-20-00 on CTIS ↗
Phase I Cardiovascular Diseases Authorised 12/08/2026

Bioavailability Comparison of Finerenone 20 mg Tablets (Test vs. Comparator Product).

Comparative bioavailability study under fasting conditions.
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
52 participants planned
Czechia
2026-527382-30-00 on CTIS ↗
Phase II Male Urogenital Diseases Authorised 12/08/2026

A phase II, single arm two-phase, clinical study of individually adapted systemic radioligand therapy with 177Lu-PSMA I&T for patients with metastatic, castration-resistant prostate cancer

Prostate cancer
Region Uppsala
80 participants planned
Sweden
2026-527110-23-00 on CTIS ↗
Phase III Neoplasms Authorised 12/08/2026

Prognostic value assessment of PSMA-T4 examination in the group of patients with triple-negative breast cancer (TNBC) qualified to radical therapy

triple-negative breast cancer
Narodowe Centrum Badan Jadrowych
100 participants planned
Poland
2025-525110-29-01 on CTIS ↗
Phase II Otorhinolaryngologic Diseases Authorised 12/08/2026

Evaluation of the efficacy, safety, and tolerability of lutetium-177-labeled PSMA ligand in patients with progression of adenoid cystic carcinoma originating from the salivary glands - an open, non-commercial clinical trial

adenoid cystic carcinoma of the salivary glands
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
31 participants planned
Poland
2026-525776-26-00 on CTIS ↗
Phase I/II Digestive System Diseases Authorised 12/08/2026

Preventive Dendritic Cell vaccination for Lynch Syndrome (PREVENT-Lynch)

Lynch Syndrome
Radboud universitair medisch centrum Stichting
13 participants planned
Netherlands
2025-524046-10-00 on CTIS ↗
Phase I Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 12/08/2026

A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and its Metabolites in Healthy Participants

This clinical trial is performed in healthy participants; the planned indication is: Neurofibromatosis Type I
Merck Healthcare KGaA
17 participants planned
Germany
2026-526403-30-00 on CTIS ↗
Phase III Neoplasms Authorised 11/08/2026

Premedication with dexamethasone for preventing interstitial lung disease in patients with breast cancer treated with trastuzumab deruxtecan

Breast Cancer
Istituto Di Ricerche Farmacologiche Mario Negri
244 participants planned
Italy
2025-521798-15-00 on CTIS ↗
Phase I Neoplasms Authorised 11/08/2026

A dose escalation and expansion study of XB010 as a single agent and combination therapy in subjects with locally advanced or metastatic solid tumors

Locally Advanced or Metastatic Solid Tumors
Exelixis Inc.
40 participants planned
Italy · Netherlands · France · Spain
2025-524805-34-00 on CTIS ↗
Phase I Neoplasms Authorised 11/08/2026

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Advanced solid tumors
Pfizer Inc.
52 participants planned
Netherlands · France · Spain
2025-522532-14-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 11/08/2026

Patient-Controlled Anesthesia for endoscopic Procedural Sedation – PCAPS study

Adenoma
Karolinska Institutet
175 participants planned
Sweden
2025-524859-31-00 on CTIS ↗
Phase I/II Mental Disorders Authorised 11/08/2026

Bioequivalence clinical trial of two formulations of quetiapine.

Healthy participants
Laboratorios Alter S.A.
36 participants planned
Spain
2026-527162-72-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 11/08/2026

A multicentre randomised study on percutaneous stellate ganglion block as first line treatment in patients with electrical storm: the STAR 2 study

electrical storm
Fondazione IRCCS Policlinico San Matteo
180 participants planned
Italy
2024-520387-34-01 on CTIS ↗
Phase II Neoplasms Authorised 11/08/2026

Valproic acid and lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma

Recurrent and/or Metastatic Adenoid Cystic Carcinom
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
15 participants planned
Italy
2026-525733-24-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 11/08/2026

J2S-MC-GZMT: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants with IBS-C

Irritable Bowel Syndrome - Constipation
Eli Lilly & Co.
70 participants planned
Belgium · Spain
2025-524974-41-00 on CTIS ↗
Phase II Hormonal diseases Authorised 10/08/2026

SDH-FLUX - Development of a new biomarker for tumor development in patients with SDHx mutation by in vivo fluxomics

paraganglioma or pheochromocytoma with surgical indication
Assistance Publique Hopitaux De Paris
10 participants planned
France
2023-506001-19-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 10/08/2026

AVISO - Assessment of Flecainide versus Bisoprolol as First-Line Treatment for Premature Ventricular Contractions: a Multicenter Randomized Clinical Trial

Premature ventricular contractions (PVC)
Assistance Publique Hopitaux De Paris
158 participants planned
France
2025-524584-20-00 on CTIS ↗
Phase II Eye Diseases Authorised 10/08/2026

A Phase 2 Multicentric Randomized Double-Blinded Efficacy and Safety Clinical Trial Comparing Several Doses of Aganirsen Eye Drops Emulsion to Extend Intravitreal Aflibercept Treatment Interval in Wet Age-Related Macular Degeneration (wAMD) Patients - SKY2 Study

Wet Age-Related Macular Degeneration (wAMD) Patients
Laboratoires Kol
162 participants planned
France
2026-526775-27-00 on CTIS ↗
Phase I Neoplasms Authorised 10/08/2026

A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Incyte Corp.
60 participants planned
Italy · Belgium · Germany · France · Spain
2026-525217-31-00 on CTIS ↗
Phase I/II Parasitic Diseases Authorised 10/08/2026

Evaluation of Interference and Synergy of Anti-Circumsporozoite Antibodies on GA2-induced Immunity

Plasmodium falciparum malaria
Leids Universitair Medisch Centrum (LUMC)
33 participants planned
Netherlands
2026-525353-37-00 on CTIS ↗
Phase I Cardiovascular Diseases Authorised 10/08/2026

A research study looking into how a single dose of the medicine NNC0537-1482 moves through the body of participants with normal or reduced kidney function

Heart failure with preserved ejection fraction
Novo Nordisk A/S
54 participants planned
Germany
2026-525271-57-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 10/08/2026

Effects of a CB1 Antagonist/Reverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase.

Stroke
Sinfatin S.L.
80 participants planned
Spain
2025-521689-86-00 on CTIS ↗
Phase I Neoplasms Authorised 10/08/2026

A Phase 1 Trial of GEN1119 in Participants with Solid Tumors

Solid Tumors
Genmab A/S
66 participants planned
Spain · France
2026-525610-62-00 on CTIS ↗
Phase III Immune system processes Authorised 10/08/2026

A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of atrasentan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN)

Primary IgAN
Novartis Pharma AG
5 participants planned
France · Spain
2025-522824-29-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 10/08/2026

Bioequivalence study 3 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

Parkinson's desease
Orion Corporation
40 participants planned
Czechia
2026-525450-11-00 on CTIS ↗
Phase II Immune System Diseases Authorised 10/08/2026

A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA) (Breakfree-AiCE)

Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA)
Celgene Corp.
3 participants planned
Germany · Denmark
2025-524993-41-00 on CTIS ↗
Phase III Mental Disorders Authorised 10/08/2026

A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate Efficacy of Roluperidone on Negative Symptoms in Adult Subjects with Schizophrenia, Followed by a 40-Week, Randomized, Double-Dummy Phase to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

Schizophrenia with negative symptoms
Minerva Neurosciences Inc.
120 participants planned
Bulgaria · Romania
2026-525925-19-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 10/08/2026

Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity

Overweight and obesity
Novo Nordisk A/S
315 participants planned
Netherlands · Belgium · Greece · Poland · Spain · Denmark · France · Bulgaria · Sweden
2025-524626-18-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 10/08/2026

The RHINOME study

Severe asthma
Region Hovedstaden
72 participants planned
Denmark
2026-527032-14-00 on CTIS ↗
Phase II Therapeutics Authorised 10/08/2026

An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma

Cutaneous T-cell lymphoma (CTCL) Mycosis fungoides
Region Midtjylland
15 participants planned
Denmark
2025-523472-23-01 on CTIS ↗
Phase III Hormonal diseases Authorised 07/08/2026

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs

Graves' Disease (GD)
Argenx
145 participants planned
Italy · Czechia · Spain · Denmark · Belgium · Romania · Latvia · France · Germany · Greece · Sweden · Poland · Lithuania · Bulgaria
2025-523333-26-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 07/08/2026

Topical Clobetasol Propionate for Inflammatory Hand osteoarthritis: A randomized trial versus placebo.(PROCLAME)

Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.
Assistance Publique Hopitaux De Paris
187 participants planned
France
2025-520678-20-00 on CTIS ↗
Phase IV Virus Diseases Authorised 07/08/2026

HORUS-Cytomegalovirus Open Proof-of-concept Exploratory trial

Cytomegalovirus infection in solid-organ transplant recipients.
Centre Hospitalier Universitaire Vaudois
90 participants planned
France · Spain
2025-524845-28-00 on CTIS ↗
Phase IV Virus Diseases Authorised 07/08/2026

A Phase 4, Pragmatic, Randomized Trial to Evaluate the Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years (DAN-COMBO)

SARS-CoV-2 infection, Influenza infection
Gentofte Hospital, Moderna Inc.
410000 participants planned
Denmark · Spain
2026-526720-49-00 on CTIS ↗
Phase I Not possible to specify Authorised 07/08/2026

A study in healthy men to test whether carbamazepine influences the amount of verducatib in the blood

Healthy
Boehringer Ingelheim International GmbH
20 participants planned
Germany
2026-525821-19-00 on CTIS ↗
Phase I Not possible to specify Authorised 07/08/2026

A study in healthy people to test how Zongertinib is taken up in the body when given as tablets made by two different manufacturers with or without food

Healthy
Boehringer Ingelheim International GmbH
56 participants planned
Germany
2026-525696-77-00 on CTIS ↗
Phase IV Virus Diseases Authorised 06/08/2026

CLINIC-CURE, a pilot exploratory clinical trial of analytical treatment interruption in people with HIV with a highly favorable profile

HIV
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
20 participants planned
Spain
2026-526395-23-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 06/08/2026

BETARGET : Randomized trial of individualizing BETA-lactam taRGET combining therapeutic drug monitoring, minimal inhibitory concentration and model-based dose adjustment, in Intensive Care Units patients with gram negative bacilli infection

sepsis
Centre Hospitalier Universitaire De Rennes
672 participants planned
France
2025-522819-42-01 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 06/08/2026

[22961] A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase 2 study to investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in adult participants with atrial fibrillation.

Atrial fibrillation
Bayer AG
105 participants planned
Belgium · Netherlands · Germany · Poland · Italy · Hungary · Bulgaria
2025-523807-31-00 on CTIS ↗
Phase I Not possible to specify Authorised 06/08/2026

A Randomized, Open label, Single Center, Single Oral Dose, Four Treatment, Four Period, Four Sequence, Crossover Bioavailability Study of Haleon Immediate Release Tablets 2X (paracetamol/naproxen 500 mg/125 mg) vs. Panadol Advance Tablets 2X (paracetamol 500 mg), Naprosyn Tablets 1X (naproxen 250 mg), administered individually in fasted conditions and Haleon Immediate Release Tablets 2X (paracetamol/naproxen 500 mg/125 mg) in fed conditions in Healthy Adult Participants

Healthy volunteers, therapeutic indication not studied
Haleon CH SARL
52 participants planned
Germany
2025-524663-20-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 06/08/2026

Spironolactone and SGLT2 inhibitor to Address Fontan circulatory failure and Enhance Resilience: The SAFER-Fontan trial

Fontan circulation
UZ Leuven
30 participants planned
Belgium
2025-524783-38-00 on CTIS ↗
Phase I Not possible to specify Authorised 06/08/2026

A study in healthy people to compare how 2 different formulations of vicadrostat / empagliflozin tablets are taken up in the body

Healthy
Boehringer Ingelheim International GmbH
36 participants planned
Germany
2025-524773-16-00 on CTIS ↗
Phase IV Bacterial Infections and Mycoses Authorised 06/08/2026

Influence of Doxycycline Use as Prophylaxis for Sexually Transmitted Infections on Bacterial Resistance and Gut Microbiota: MiDoxyR-PEP Study

Colonization by methicillin-resistant S. aureus and gut microbiota in users of pre-exposure prophylaxis (PrEP) and people living with HIV (PLHIV) with STIs.
Instituto De Investigacion Marques De Valdecilla
392 participants planned
Spain
2025-525150-19-01 on CTIS ↗
Phase I/II Neoplasms Authorised 06/08/2026

Trial to study the safety, pharmacokinetics and preliminary antitumour activity of ODM-216 in patients with cancer

Advanced solid tumours
Orion Corporation
104 participants planned
Spain
2026-525864-17-00 on CTIS ↗
Phase II Immune System Diseases Authorised 05/08/2026

VIP-1 : Preclinical type 1 diabetes: the VIP-1 Study

People with stage 1 or stage 2 T1D between the ages of 7 and 45
Assistance Publique Hopitaux De Paris
50 participants planned
France
2025-524318-27-00 on CTIS ↗
Phase III Immune System Diseases Authorised 05/08/2026

A Phase 3, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents with HIV who are Virologically Suppressed on ART

HIV Infections
Viiv Healthcare UK Limited
81 participants planned
Spain
2024-518511-19-00 on CTIS ↗
Phase I Hormonal diseases Authorised 05/08/2026

An open label, randomized, single-dose, two-treatment, two-sequence, two-period, cross-over pilot comparative bioavailability study comparing Empagliflozin and Metformin f.c. tabs (12.5+1000) mg, VIANEX S.A., Greece versus Synjardy 12.5 mg/1,000 mg film-coated tablets, Boehringer Ingelheim International GmbH, Germany, in healthy male and female volunteers under fasting conditions.

treatment of diabetes
Vianex S.A.
18 participants planned
Czechia
2026-526397-17-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 05/08/2026

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study of YMI024 to assess efficacy in reducing inflammatory markers, safety, and tolerability in adults with stable coronary artery disease and elevated hsCRP

Chronic Kidney Disease, Heart Failure, Coronary Artery disease
Novartis Pharma AG
43 participants planned
Germany
2026-525974-21-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 04/08/2026

ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment

Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES), Asthma
AstraZeneca AB
94 participants planned
Denmark · Belgium · France · Italy · Netherlands · Austria · Poland
2025-523307-29-00 on CTIS ↗
Phase IV Nutritional and Metabolic Diseases Authorised 04/08/2026

A Phase IV, Randomized Controlled Trial to Evaluate the Effects of Resistance Training Versus Usual Care on Thigh Muscle Volume During Treatment with the Dual GIP/GLP-1 Receptor Agonist Tirzepatide in Adults with Obesity

Obesity
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
150 participants planned
Germany
2026-526200-69-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 04/08/2026

A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)

Idiopathic Pulmonary Fibrosis
AstraZeneca AB
139 participants planned
Poland · Hungary · Netherlands · Germany · Spain · Greece · Bulgaria · Italy · France · Denmark
2025-525016-41-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 04/08/2026

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Placebo in Adults with Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)

type 2 diabetes mellitus
AstraZeneca AB
200 participants planned
Poland · Germany · Bulgaria · Czechia
2025-523935-20-00 on CTIS ↗
Phase I Not possible to specify Authorised 04/08/2026

Study in healthy volunteers to evaluate how the body processes Iadademstat and if food affects it

Healthy Volunteers
Oryzon Genomics S.A.
30 participants planned
Spain
2026-525953-35-00 on CTIS ↗
Phase I Neoplasms Authorised 04/08/2026

A study of enzomenib investigating potential drug-drug interactions and the effect of liver impairment in adult patients with advanced cancer

Advanced Cancer
Sumitomo Pharma America Inc.
43 participants planned
Spain · Bulgaria · Poland · Romania
2025-524652-63-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 03/08/2026

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron compared with Placebo in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)

type 2 diabetes mellitus
AstraZeneca AB
183 participants planned
Germany · Bulgaria · Spain · Denmark
2025-523940-12-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 03/08/2026

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared with Elecoglipron Alone and Dapagliflozin Alone, in Adults with Type 2 Diabetes Mellitus (Eluminate-5)

type 2 diabetes mellitus
AstraZeneca AB
360 participants planned
Slovakia · Poland · Czechia · Germany · Hungary · Greece · Denmark
2025-523941-81-00 on CTIS ↗
Phase IV Musculoskeletal Diseases Authorised 03/08/2026

Non-inferiority of surgical treatment of cartilage defects of the knee with autologous minced cartilage implantation (AMCI) and matrix-asscociated autologous chondrocyte implantation with respect to KOOS at 24 months (M ACI) - MinCaRCT

Full-thickness cartilage defects of the knee
Medical Center - University Of Freiburg
166 participants planned
Germany
2026-526179-49-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 03/08/2026

RUBY study « Randomized controlled trial testing the efficacy of corticosteroid therapy versus placebo in fibrotic hypersensitivity pneumonitis.»

Adult patients with a diagnosis of fibrotic Hypersensitivity Pneumonitis (HP) (“definite” or “high confidence”) after multi-disciplinary discussion (MDD) with a mild to moderate disease severity, and never treated for fibrotic HP.
Assistance Publique Hopitaux De Paris
120 participants planned
France
2025-521591-64-00 on CTIS ↗
Phase III Neoplasms Authorised 03/08/2026

A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy

Acute Myeloid Leukemia
AbbVie Deutschland GmbH & Co. KG
25 participants planned
France · Austria · Spain
2025-523724-47-00 on CTIS ↗
Phase I Neoplasms Authorised 03/08/2026

A First-in-Human Study of INCA035784 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Incyte Corp.
40 participants planned
Italy · Belgium · Germany
2026-525360-18-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 03/08/2026

A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)

Systemic sclerosis
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
179 participants planned
Denmark · Hungary · Sweden · Netherlands · Germany · Belgium · France · Greece · Norway · Finland · Czechia · Portugal · Bulgaria · Spain · Austria · Romania · Croatia · Poland · Estonia · Italy · Lithuania
2025-523884-39-00 on CTIS ↗
Phase I Neoplasms Authorised 03/08/2026

Feasibility clinical trial of the sequential combination of AloCelyvir and activated tumor-infiltrating lymphocytes (TILs) for the treatment of children and young adults with advanced neuroblastoma

High-risk relapsed/refractory (R/R) neuroblastoma (NB).
Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa
15 participants planned
Spain
2025-522006-21-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 03/08/2026

Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.

Epilepsy
Ovid Therapeutics Inc.
12 participants planned
Netherlands
2026-527114-23-00 on CTIS ↗
Phase I Immune System Diseases Authorised 03/08/2026

Treatment of patients with autoantibody-positive autoimmune diseases and severe interstitial lung fibrosis with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - a single center Phase I/II clinical trial (HD-CAR-ILD-1)

Therapy-resistant and progressing lung fibrosis in the course of an autoantibody-positive autoimmune disease like Systemic Sclerosis, ANCA-associated Vasculitis, seropositive Rheumatoid Arthritis, Sjögren’s disease, anti-Synthetase Syndrome or other autoimmune diseases
Universitaetsklinikum Heidelberg AöR
10 participants planned
Germany
2024-519592-26-00 on CTIS ↗
Phase III Immune System Diseases Authorised 03/08/2026

A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease

Moderately to Severely Active Crohn’s Disease
Janssen Cilag International
194 participants planned
Norway · Romania · Austria · Italy · Slovakia · Germany · Hungary · Netherlands · Belgium · France · Portugal · Czechia · Poland · Spain · Greece
2026-525922-39-00 on CTIS ↗
Phase III Immune System Diseases Authorised 03/08/2026

A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis
Janssen Cilag International
302 participants planned
France · Bulgaria · Romania · Slovakia · Norway · Denmark · Greece · Italy · Austria · Poland · Netherlands · Czechia · Germany · Belgium · Spain · Hungary · Portugal
2026-525923-26-00 on CTIS ↗
Phase I Immune System Diseases Authorised 02/08/2026

A Phase I Study to Evaluate ELA822

Healthy Volunteers
Electra Therapeutics Inc.
45 participants planned
Austria
2025-524911-34-00 on CTIS ↗
Phase II Therapeutics Authorised 01/08/2026

Botulinum toxin A in the Treatment of Chronic Postsurgical Pain in Lung Cancer Patients: A feasibility study

Chronic postsurgical pain (CPSP)
Aalborg University Hospital
15 participants planned
Denmark
2026-525669-33-00 on CTIS ↗
Phase II Mental Disorders Authorised 01/08/2026

The Danish Anorexia Nervosa Psilocybin RCT (DANP-RCT). A Randomised, Active-Placebo-Controlled, Triple-blind, Superiority Study of Psilocybin-Assisted Acceptance and Commitment Therapy (ACT) in the Treatment of Treatment-resistant Anorexia Nervosa.

Anorexia nervosa
Slagelse Hospital
62 participants planned
Denmark
2025-524939-39-02 on CTIS ↗
Phase I Nervous System Diseases Authorised 31/07/2026

A Randomised, Placebo‑Controlled Trial to Assess Effect of IMU‑838 on QT/QTc

Multiple sclerosis
Immunic AG
20 participants planned
Belgium
2026-526859-54-00 on CTIS ↗
Phase I Neoplasms Authorised 31/07/2026

A study to test how well different doses of BI 3822971 are tolerated by people with advanced cancer (solid tumours)

solid tumours
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
39 participants planned
Spain
2026-525785-22-00 on CTIS ↗
Phase III Anesthesia and Analgesia Authorised 31/07/2026

Perioperative Intravenous Metamizole in Laparoscopic Cholecystectomy: A rondomized, double blind, clinical trial.

Post operative pain relief in Patients undergoing laparoscopic cystectomy in day-surgery clinic
UZ Leuven
76 participants planned
Belgium
2026-526531-18-00 on CTIS ↗
Phase II Pathological Conditions, Signs and Symptoms Authorised 31/07/2026

An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T Cell Engager OM336 for Desensitization of Kidney Transplant Candidates

End stage renal failure
Medical University Of Vienna
6 participants planned
Austria
2025-523222-40-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 31/07/2026

A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients ≥ 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.

Drug resistant focal epilepsy related to focal cortical dysplasia
PannTheraPi
15 participants planned
France
2026-525161-40-00 on CTIS ↗
Phase I Pathological Conditions, Signs and Symptoms Authorised 30/07/2026

Whole body HER2 quantification with 89Zr-Trastuzumab PET/CT to asses Zr-trastuzumab accumulation in HER2-mutated and HER2-overexpressing metastatic non-small cell lung cancer

HER2 mutation positive NSCLC
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
20 participants planned
Netherlands
2026-525568-17-00 on CTIS ↗
Phase I/II Nervous System Diseases Authorised 30/07/2026

A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3

Spinocerebellar ataxia type 3
Institut De Recherches Internationales Servier IRIS
50 participants planned
France · Denmark · Spain · Portugal
2025-525111-17-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 30/07/2026

Nav 1.8 and 1.7 combo trial

Pain
Niroda Therapeutics Inc.
96 participants planned
Netherlands
2026-526867-39-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 30/07/2026

Bioequivalence of Tramadol retard 200 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions

Not applicable (submitted trial is a bioavailability trial in healthy participants).
Laboratorios Cinfa S.A.
36 participants planned
Czechia
2026-525836-41-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 30/07/2026

J3L-MC-EZEJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event

Lipoprotein(a), Atherosclerosis, Cardiovascular Diseases
Eli Lilly & Co.
145 participants planned
Hungary · Czechia · Spain · Netherlands
2025-524858-34-00 on CTIS ↗
Phase I Immune System Diseases Authorised 30/07/2026

Study to assess the plasma concentration of rilzabrutinib given as a tablet to adult participants with severe renal impairment compared to matched participants with normal renal function

Renal Impairment
Sanofi-Aventis Recherche & Developpement
8 participants planned
Germany
2026-525707-27-00 on CTIS ↗
Phase III Neoplasms Authorised 29/07/2026

A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1)

Follicular Lymphoma
AstraZeneca AB
15 participants planned
Denmark
2023-510098-33-01 on CTIS ↗
Phase I Neoplasms Authorised 29/07/2026

A Phase 1a/1b, multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PLN-101095 alone and in combination with pembrolizumab in adults with advanced or metastatic solid tumors following progression on immune checkpoint inhibitor therapy

Advanced or metastatic solid tumours
Pliant Therapeutics Inc.
15 participants planned
Spain
2026-526116-36-00 on CTIS ↗
Phase III Mental Disorders Authorised 29/07/2026

B-HAPPI: Bipolar disorder and high-dose adjunctive pramipexole for anhedonic depression – a phase III, double-blind, randomized controlled trial

Bipolar disorder
Region Skane
186 participants planned
Sweden
2026-526383-20-00 on CTIS ↗
Phase I/II Skin and Connective Tissue Diseases Authorised 29/07/2026

A Phase I/II, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age

Acne
Sanofi Pasteur Inc.
189 participants planned
Spain · Germany · Poland
2025-521740-38-00 on CTIS ↗
Phase IV Mental Disorders Authorised 29/07/2026

Effectiveness of Trazodone on Emotional Blunting in Patients with Major Depressive: a Phase IV, Open-label, clinical study

Major depressive disorder (MDD)
Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
120 participants planned
Bulgaria · Poland · Hungary
2025-523267-38-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 29/07/2026

A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)

Heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF); on background SGLT2i.
AstraZeneca AB
2343 participants planned
Spain · Hungary · Germany · Poland · Italy · Bulgaria · Netherlands · Austria · Romania · Sweden · France · Greece · Slovakia · Czechia
2026-526304-79-00 on CTIS ↗
Phase I Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 29/07/2026

An Open-label Phase 1 Study in Healthy Adult Participants to Investigate the Effect of Itraconazole on the Blood Levels of Engasertib

This clinical trial is performed in healthy participants; the planned indication: Treatment of Hereditary hemorrhagic telangiectasia (HHT)
Vaderis Therapeutics AG
27 participants planned
Germany
2026-526311-11-00 on CTIS ↗
Phase II Neoplasms Authorised 28/07/2026

A Phase 2 Study of Alisertib in Combination with Paclitaxel in Patients with Small Cell Lung Cancer

Small Cell Lung Cancer (SCLC)
Puma Biotechnology Inc.
30 participants planned
France · Poland · Spain
2026-525382-47-00 on CTIS ↗
Phase I/II Neoplasms Authorised 28/07/2026

Melanoma-TBK1-inhibitor enhanced Immuno Therapy with Checkpoint Inhibitors: a Phase IB/II Trial in Unresectable Stage III or Stage IV Cutaneous Melanoma

Unresectable Stage III or Stage IV Cutaneous Melanoma
Karolinska University Hospital
105 participants planned
Sweden
2026-526821-16-00 on CTIS ↗
Phase IV Nervous System Diseases Authorised 28/07/2026

Comparative study of two vaccination schedules for the subunit Herpes Zoster vaccine in Multiple Sclerosis and Neuromyelitis optica spectrum disease patients treated with anti-CD20 therapy: an open-label randomised controlled trial.

Multiple Sclerosis and Neuromyelitis optica spectrum
Centre Hospitalier Universitaire De Toulouse
160 participants planned
France
2025-525106-37-00 on CTIS ↗
Phase II Immune System Diseases Authorised 28/07/2026

OBINUSS - Safety and efficacy of obinutuzumab in systemic sclerosis: a phase II, randomized, double-blinded versus placebo-controlled trial

Patients with newly or active diffuse Systemic sclerosis at the time of screening.
Assistance Publique Hopitaux De Paris
74 participants planned
France
2025-524003-68-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 28/07/2026

STRategiEs for Antiplatelet Management foLlowIng acute coroNary syndromE (STREAMLINE)

ischemic heart disease
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz
3500 participants planned
Spain · Norway
2026-525933-22-00 on CTIS ↗
Phase I Neoplasms Authorised 27/07/2026

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination with Bevacizumab in Adult Participants with Ovarian Cancer

Ovarian Cancer
AbbVie Deutschland GmbH & Co. KG
44 participants planned
Portugal · Denmark · Spain · France
2025-522209-40-00 on CTIS ↗
Phase I Neoplasms Authorised 27/07/2026

A Phase 1 Study of PRT12396 in Participants with Select Myeloproliferative Neoplasms

Post-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Intermediate-1, Intermediate-2, or High-Risk Primary Myelofibrosis, High-risk Polycythemia Vera
Prelude Therapeutics Inc.
22 participants planned
Italy · France · Spain
2026-525484-40-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 27/07/2026

A Randomized Controlled Study Evaluating Short-Term Dual Antiplatelet Therapy with Low-Dose Ticagrelor (60 mg) Followed by Monotherapy versus Standard-Duration Dual Antiplatelet Therapy with Clopidogrel in Patients with Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: the STELAR trial

Chronic Coronary Syndrome in patients undergoing percutaneous coronary intervention (PCI)
Azienda Ospedaliera Universitaria Gaetano Martino Messina
500 participants planned
Italy
2026-526368-18-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 27/07/2026

A first-in-human, randomized, double-blind, placebo-controlled, 3-part study assessing the safety, tolerability, pharmacodynamics and pharmacokinetics of GL0071 after single and repeated ascending subcutaneous doses in healthy normal weight, overweight and obese participants, as well as a 12-week treatment randomized, double blind, placebo-controlled exploratory Proof-of-Concept study in overweight and obese participants.

Type 2 diabetes mellitus, Overweight
Sun Pharmaceutical Industries Limited
124 participants planned
Belgium
2025-524233-45-00 on CTIS ↗
Phase II Neoplasms Authorised 27/07/2026

A Cancer Research UK Phase II trial of CY-101 given via intratumoural administration in locally advanced or metastatic adrenocortical carcinoma (CLARITY)

LOCALLY ADVANCED OR METASTATIC ADRENOCORTICAL CARCINOMA
Cancer Research UK
26 participants planned
Spain · France · Germany · Norway
2025-522757-19-00 on CTIS ↗
Phase II Neoplasms Authorised 27/07/2026

A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination with Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
Janssen Cilag International
6 participants planned
Spain
2025-524816-13-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 27/07/2026

A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes

Participants with obesity with or without type 2 diabetes
Novo Nordisk A/S
1140 participants planned
Greece · Portugal · France · Slovakia · Bulgaria · Netherlands · Romania · Italy · Austria · Poland · Hungary · Spain · Czechia · Belgium
2025-522488-14-00 on CTIS ↗
Phase III Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 27/07/2026

4TAZPower: A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome

Barth Syndrome
Stealth Biotherapeutics Inc.
22 participants planned
Ireland · Netherlands · France · Italy
2025-523837-25-00 on CTIS ↗
Phase I/II Neoplasms Authorised 27/07/2026

Phase I/II Trial to Determine Safety and Efficacy of non-Viral Allogeneic Dual CD123/33-Chimeric Antigen Receptor CIK (CARCIK-CD123/33) Cells in Adult and Pediatric Patients with Relapse/Refractory Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Acute myeloid leukemia and Blastic plasmacytoid dendritic cell neoplasm
Fondazione Tettamanti, Fondazione IRCCS San Gerardo Dei Tintori
18 participants planned
Italy
2025-524977-18-00 on CTIS ↗
Phase I Parasitic Diseases Authorised 27/07/2026

A clinical trial of MK-3868 in healthy participants (MK-3868-001)

Malaria
Merck Sharp & Dohme LLC
16 participants planned
Belgium
2026-526674-17-00 on CTIS ↗
Phase III Neoplasms Authorised 27/07/2026

A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer
AbbVie Deutschland GmbH & Co. KG
125 participants planned
Italy · Greece · Spain · Belgium · France · Austria · Germany
2025-523819-11-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 27/07/2026

Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients with Atrial Fibrillation and Rapid Ventricular Rate (RVR). The ReVeRA-301 Trial.

Atrial Fibrillation
Milestone Pharmaceuticals Inc.
200 participants planned
Netherlands
2024-516251-40-01 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 27/07/2026

Within-Patient Comparison of Serum Transthyretin Response to Tafamidis Versus Acoramidis: A Pilot Crossover Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Medical University Of Vienna
10 participants planned
Austria
2026-526526-41-01 on CTIS ↗
Phase IV Therapeutics Authorised 27/07/2026

Thromboprophylaxis with apixaban during neoadjuvant therapy for muscle-invasive bladder cancer (ACB): An international randomized controlled trial evaluating apixaban versus no anticoagulation in patients scheduled to undergo radical cystectomy or chemoradiotherapy for muscle-invasive bladder cancer

Venous thromboembolism (in bladder cancer patients)
HUS-Yhtymae
210 participants planned
Finland
2024-518861-90-00 on CTIS ↗
Phase I Not possible to specify Authorised 27/07/2026

A study in healthy people to measure how different doses of verducatib affect the heart

Healthy volunteer trial
Boehringer Ingelheim International GmbH
56 participants planned
Germany
2026-525813-30-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 27/07/2026

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)

Participants Living with Obesity or Overweight with at least 1 comorbidity with or without Type 2 Diabetes Mellitus
AstraZeneca AB
1010 participants planned
Spain · Germany · Italy · Poland
2025-524688-19-00 on CTIS ↗
Phase III Neoplasms Authorised 27/07/2026

An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

Advanced or Metastatic HR+/HER2- Breast Cancer
BeOne Medicines I GmbH
233 participants planned
Poland · Italy · Germany · France · Spain
2025-523960-19-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 24/07/2026

Evaluation of the effect of botulinum toxin on refractory upper limb rest tremor in parkinsonian patients, double-blind, placebo-controlled cross-over study : TOX PARK

parkinson disease
Centre Hospitalier Universitaire De Toulouse
39 participants planned
France
2026-525862-23-00 on CTIS ↗
Phase II Neoplasms Authorised 24/07/2026

DECREASE-IPC 2025-068 : De-Ecalating neoadjuvant Chemoimmunotherapy in early triple-negative BREASt cancer

triple‑negative breast cancer
Institut Paoli Calmettes
84 participants planned
France
2025-525040-18-00 on CTIS ↗
Phase II Not possible to specify Authorised 24/07/2026

functional imaging of digital osteoarthritis and rheumatoid arthritis using 99mTc-NTP15-5 in nuclear medicine : phase II clinical study

Arthritis rheumatoid and finger osteoarthritis
Centre Jean Perrin
80 participants planned
France
2025-523650-14-00 on CTIS ↗
Phase IV Therapeutics Authorised 24/07/2026

VATS or Intrapleural Enzymatic Therapy for patientS with empyema (the VIETS trial)

Parapneumonic pleural infection/pleural empyema
Amsterdam UMC Stichting
164 participants planned
Netherlands
2026-526289-25-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 24/07/2026

Immune Cell Therapy for People with Early, Active Multiple Sclerosis

Newly diagnosed highly-active Multiple Sclerosis
Medizinische Hochschule Hannover
10 participants planned
Germany
2025-522409-39-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 24/07/2026

An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam

Spinal Muscular Atrophy
Biogen Idec Research Limited
40 participants planned
Finland · Spain · Italy · Poland · Ireland · Germany · France
2025-524054-34-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 24/07/2026

A randomised active-controlled trial to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation

non-valvular atrial fibrillation
Ribocure Pharmaceuticals AB
150 participants planned
Norway · Denmark · Poland · Sweden
2026-525417-31-00 on CTIS ↗
Phase I Diagnosis Authorised 24/07/2026

161Tb-labeled Gastrin Analogue - A Novel Tool for Precision Treatment of Advanced Medullary Thyroid Cancer

Thyroid cancer
Uniwersytet Jagiellonski Collegium Medicum
30 participants planned
Poland
2025-524951-30-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 24/07/2026

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)

Chronic kidney disease (CKD) in adults, with specified ranges of eGFR and albuminuria (UACR), irrespective of T2DM status; background SGLT2i dapagliflozin 10 mg as GDMT.
AstraZeneca AB
1600 participants planned
Czechia · Italy · Hungary · Romania · Bulgaria · Sweden · Denmark · Poland · Spain · Norway · Finland · Greece · France · Germany
2025-523994-41-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 23/07/2026

Phase 3 Randomized Study of Teclistamab and Talquetamab (Tec-Tal) Versus Daratumumab and Lenalidomide (DR) in Minimal Residual Disease (MRD) Positive Patients With Newly Diagnosed Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation (TiTan)

Multiple myeloma
Polish Myeloma Consortium
248 participants planned
Poland
2025-525097-11-00 on CTIS ↗
Phase I Respiratory Tract Diseases Authorised 23/07/2026

A Study to Evaluate the Safety and Activity of an Inhaled Investigational Drug (RO7616605) in Healthy Volunteers and Participants With COPD

Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
Genentech Inc.
104 participants planned
Germany
2025-525042-22-00 on CTIS ↗
Phase II Neoplasms Authorised 23/07/2026

Immune dynamics and biomarkers of anti-tumor response in BMS-986340 (anti-CCR8) and nivolumab (anti-PD-1) co-treatment of metastatic tumors

Metastatic solid tumors, with the following specific indications: Non–Small Cell Lung Cancer (NSCLC), metastatic, PD-(L)1–refractory/resistant Gastric adenocarcinoma, metastatic, PD-(L)1–refractory/resistant Colorectal cancer (microsatellite stable, MSS), metastatic, immunotherapy‑naïve Pancreatic adenocarcinoma, metastatic, immunotherapy‑naïve
Humanitas Mirasole S.p.A., Fondazione Humanitas Per La Ricerca Ets
30 participants planned
Italy
2025-524125-40-01 on CTIS ↗
Phase II Immune System Diseases Authorised 23/07/2026

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of SIR9900 in Patients with VEXAS Syndrome (SIVEX)

VEXAS Syndrome
Sironax USA Inc.
24 participants planned
Italy
2025-524918-28-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 23/07/2026

IKF-099/D-FLOT-TNT Total Neoadjuvant Treatment with preoperative FLOT/Durvalumab plus postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
91 participants planned
Germany · Spain
2026-525185-21-00 on CTIS ↗
Phase III Hormonal diseases Authorised 23/07/2026

A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia

Classic Congenital Adrenal Hyperplasia (CAH)
Neurocrine Biosciences Inc.
71 participants planned
Czechia · Germany · Sweden · Portugal · Romania · Bulgaria · Italy · Austria · Spain
2025-524282-24-00 on CTIS ↗
Phase III Not possible to specify Authorised 23/07/2026

Prospective, multicentre, open-label, single arm trial on contraceptive efficacy, safety and tolerability of LPRI-CF113 (Drospirenone 4 mg + 2.8 mg) during 13 cycles.

No medical condition
Chemo Research S.L.
1550 participants planned
Sweden · Czechia · Spain · Hungary · Poland · Finland · Romania
2026-525727-24-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 23/07/2026

A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants with Huntington’s Disease

Huntington’s Disease
Skyhawk Therapeutics Inc.
110 participants planned
Germany · Spain
2025-522263-14-00 on CTIS ↗
Phase I/II Respiratory Tract Diseases Authorised 22/07/2026

A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC

Advanced ALK-positive NSCLC
Triana Biomedicines Inc.
4 participants planned
France · Italy · Germany · Spain
2025-524418-27-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 22/07/2026

An unblinded, single arm, pilot observational study to test the safety, tolerability, immunogenicity and the biological effects of TRB-001 vaccination in individuals who have previously undergone aSyn immunotherapy

Parkinson's disease
Tridem Bioscience FlexCo
8 participants planned
Austria
2026-526294-42-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 22/07/2026

Real-World Effectiveness of the Adjuvanted RSVPreF3 Vaccine in Adults ≥60 Years: A Pragmatic Randomized Trial (BronquiVal)

Respiratory syncytial virus infection–related respiratory disease
Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana
100000 participants planned
Spain
2026-526804-59-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 22/07/2026

Colchicine for the Reduction of Dependency and Vascular Events after an Acute Intracerebral Hemorrhage (CoVasc-ICH2)

Major cardiovascular events (MACE), spontaneous intracerebral hemorrhage
Hamilton Health Sciences Corporation, PHRI Population Health Research Institute International
312 participants planned
Spain · Belgium
2025-523435-18-00 on CTIS ↗
Phase IV Immune System Diseases Authorised 22/07/2026

Do GLP-1 based therapies improve the immunological response to vaccination in diabetes?

Diabetes
Radboud universitair medisch centrum Stichting
100 participants planned
Netherlands
2026-525909-13-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 22/07/2026

Local and systemic immune modulation by Rilvegostomig (AZD2936) in the treatment of advanced gastric cancer (RILVE Project)

advanced gastric cancer
Vall D Hebron Institute Of Oncology
38 participants planned
Spain
2026-525620-23-00 on CTIS ↗
Phase I Neoplasms Authorised 22/07/2026

Tarlatamab Before and After Surgery for Recurrent High-Grade Glioma

surgically resectable recurrent high-grade glioma
Vall D Hebron Institute Of Oncology
10 participants planned
Spain
2025-524359-30-00 on CTIS ↗
Phase I/II Immune System Diseases Authorised 22/07/2026

A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants with Refractory Rheumatoid Arthritis

Refractory, difficult-to-treat Rheumatoid Arthritis
Bristol-Myers Squibb Services Unlimited Company
21 participants planned
Poland · Italy · Spain · Germany
2025-520666-22-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 22/07/2026

A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Oral Semaglutide in Adults with Type 2 Diabetes Mellitus (Eluminate-2)

type 2 diabetes mellitus
AstraZeneca AB
335 participants planned
Poland · Hungary · Italy · Bulgaria · Germany
2025-523933-24-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 22/07/2026

A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)

Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)
Alnylam Pharmaceuticals Inc.
17 participants planned
Italy · Netherlands · Spain · Germany · Ireland
2025-523390-42-00 on CTIS ↗
Phase I Neoplasms Authorised 21/07/2026

Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors

Advanced Malignant Tumors; High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb Services Unlimited Company
20 participants planned
Spain · France · Italy
2025-523067-38-01 on CTIS ↗
Phase III Digestive System Diseases Authorised 21/07/2026

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis
Ipsen Bioscience Inc.
127 participants planned
Spain · Sweden · Germany · Romania · Finland · Portugal · Austria · Italy · Denmark · Czechia · France · Netherlands · Poland · Belgium · Norway
2026-525242-29-00 on CTIS ↗
Phase II Bacterial Infections and Mycoses Authorised 21/07/2026

Randomized Controlled Trial Assessing the Effectiveness and Safety of Fecal Microbiota Transfer for VRE Eradication in Immunocompromised Patients (EU CTR, Phase II) – VRE-ex

Intestinal colonization with vancomycin-resistant enterococci (VRE)
Fraunhofer Institute For Translational Medicine And Pharmacology ITMP
42 participants planned
Germany
2026-525632-41-00 on CTIS ↗
Phase I/II Neoplasms Authorised 21/07/2026

A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and dose optimization study of GSK5471713 in adult participants with metastatic castration resistant prostate cancer (mCRPC).

Neoplasms, Prostate
Glaxosmithkline Research & Development Limited
18 participants planned
Netherlands · France · Spain
2025-523874-17-00 on CTIS ↗
Phase I Neoplasms Authorised 21/07/2026

A more sustainable perioperative treatment regimen for gastroesophageal cancer —replacing 5-FU with capecitabine within the FLOT regimen

Gastric Cancer, Esophageal cancer
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
14 participants planned
Netherlands
2026-526209-13-00 on CTIS ↗
Phase II Immune System Diseases Authorised 21/07/2026

A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS)

newly diagnosed amyloid light chain amyloidosis
Glaxosmithkline Research & Development Limited
17 participants planned
Italy · Greece · Spain
2025-522803-60-00 on CTIS ↗
Phase III Virus Diseases Authorised 21/07/2026

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens

HIV-1
Gilead Sciences Inc.
183 participants planned
Poland · Italy · France · Spain · Germany · Netherlands
2025-524336-19-00 on CTIS ↗
Phase III Virus Diseases Authorised 21/07/2026

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

HIV-1
Gilead Sciences Inc.
183 participants planned
Netherlands · Poland · Germany · France · Spain · Italy
2025-524335-39-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 21/07/2026

A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice-daily Delgocitinib Cream in Adult Participants with Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period

Lichen Sclerosus
Leo Pharma A/S
205 participants planned
Italy · France · Spain · Poland · Germany
2025-524873-17-00 on CTIS ↗
Phase II Neoplasms Authorised 21/07/2026

J2J-MC-JZLL - preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women with Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

Breast Neoplasms
Eli Lilly & Co.
361 participants planned
Belgium · France · Italy · Germany
2025-523258-15-00 on CTIS ↗
Phase II Bacterial Infections and Mycoses Authorised 20/07/2026

DOXYCYCLINE PENETRATION INTO BONE AND JOINT.

Patients requiring total hip arthroplasty for coxofemoral osteoarthritis
Centre Hospitalier Universitaire De Caen Normandie
30 participants planned
France
2025-524744-36-00 on CTIS ↗
Phase I Neoplasms Authorised 20/07/2026

Study of MX006 in Patients With Advanced and/or Metastatic Tumors known to express B7-H3

Advanced Solid Tumor Types Known to Express B7-H3
Myricx Pharma Limited
40 participants planned
Spain
2025-524929-41-00 on CTIS ↗
Phase II Male Urogenital Diseases Authorised 20/07/2026

Randomized Phase II study of multi-peptide vaccination and bispecific PSMAxCD3 antibody treatment in patients with biochemical relapse of prostate cancer

biochemical relapse of prostate cancer
Universitaetsklinikum Tuebingen AöR
84 participants planned
Germany
2025-522144-41-00 on CTIS ↗
Phase II Neoplasms Authorised 20/07/2026

HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)

chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
58 participants planned
Netherlands
2025-524842-89-00 on CTIS ↗
Phase II Neoplasms Authorised 20/07/2026

A PHASE II, SINGLE ARM, OPEN LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED A PRIOR BCMA TARGETING CAR T-CELL THERAPY

Multiple Myeloma (MM)
F. Hoffmann-La Roche AG
45 participants planned
Germany
2026-525736-42-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 20/07/2026

A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
AstraZeneca AB
158 participants planned
Germany · Italy · Spain · France · Sweden
2025-523908-75-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 20/07/2026

A placebo-controlled comparability study to compare two presentations of cagrilintide for weight management in participants with overweight or obesity

Participants with overweight or obesity
Novo Nordisk A/S
171 participants planned
Sweden · Greece · Hungary · Portugal
2025-524249-29-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 20/07/2026

A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease

Huntington’s Disease
Novartis Pharma AG
368 participants planned
Norway · Poland · Spain · Sweden · Bulgaria · Netherlands · Finland · Portugal · Austria · Italy · Greece · Ireland · Czechia · France · Romania · Belgium · Germany · Denmark · Slovakia · Hungary
2025-522227-99-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 20/07/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

Narcolepsy Type 1
Alkermes Inc.
116 participants planned
Sweden · Finland · Belgium · Spain · Austria · Netherlands · France · Norway · Germany · Italy · Poland
2025-524711-36-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 20/07/2026

A Phase 2a, multi centric, open label clinical study to explore the safety and tolerability, the pharmacokinetics and pharmacodynamics profile and first signs of efficacy of PTI5803 administered as adjunctive therapy with a 3-dose escalation regimen in patients >= 14 years of age with drug-resistant seizures associated to focal cortical dysplasia, followed by an optional open-label extension study.

Drug resistant seizures associated to Focal Cortical Dysplasia
PannTheraPi
15 participants planned
France
2026-525162-21-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 20/07/2026

Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Subjects (age 12 to <18 years) with Homozygous Familial Hypercholesterolemia (SPRUCE)

Homozygous Familial Hypercholesterolemia (HoFH)
Arrowhead Pharmaceuticals Inc.
9 participants planned
Netherlands · Denmark · Norway · Sweden · Poland
2025-523662-24-00 on CTIS ↗
Phase I Mental Disorders Authorised 20/07/2026

A study comparing the new drugs PG511/PG521/PG531 produced by Celon Pharma SA with the drug PG203 in healthy volunteers.

Treatment of psychotic disorders like schizophrenia Treatment of levodopa-induced dyskinesia in Parkinson's disease
Celon Pharma S.A.
68 participants planned
Poland
2025-524936-20-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 20/07/2026

An open label multicenter phase II study to investigate the efficacy, safety and tolerability of the Obe-cel in patients with minimal residual disease (MRD) of Philadelphia negative (Ph neg) B-precursor acute lymphoblastic leukaemia (B-ALL) - GMALL-OBECEL

Ph-negative CD19 positive B-precursor ALL patients in CR1 with molecular failure defined as MRD of 10-4 or greater after induction II of front-line therapy
Goethe University Frankfurt
20 participants planned
Germany
2025-524169-26-00 on CTIS ↗
Phase I/II Neoplasms Authorised 20/07/2026

A phase I/IIa safety, dose finding and feasibility trial of CD30/CEA CART in patients with liver metastases from CEA positive colorectal adenocarcinoma

Colorectal Adenocarcinoma
Universitaetsklinikum Regensburg AöR
18 participants planned
Germany
2026-526225-18-00 on CTIS ↗
Phase III Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 17/07/2026

Intrathecal Administration of MELPIDA For Hereditary Spastic Paraplegia Type 50 (SPG50): A multicenter Phase 3, Open-Label Trial with Matched Prospective Concurrent Control Arm (CT-MEL-03)

Hereditary Spastic Paraplegia Type 50 (SPG50)
Elpida Therapeutics SPC
12 participants planned
Spain
2025-524576-28-00 on CTIS ↗
Phase II Pathological Conditions, Signs and Symptoms Authorised 17/07/2026

SETRAPED : A prospective, multicenter study evaluating the efficacy and tolerance of transmucosal midazolam for proportionate palliative sedation in children with refractory symptoms

Children with refractory symptoms
Centre Leon Berard
50 participants planned
France
2025-523840-11-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 17/07/2026

Triple oral therapy with bempedoic acid vs usual care in early lipid management of patients with acute coronary syndrome

Acute Coronary Syndrome
Fondazione Per Il Tuo Cuore Onlus Denominabile Anche Fondazione Italiana Per La Lotta Alle Malattie Cardiovascolari Onlus Ed Anche Heart Care Foundation Hcf Onlus
600 participants planned
Italy
2026-525740-15-00 on CTIS ↗
Phase I Not possible to specify Authorised 17/07/2026

Bioequivalence study of Vitamin D3 Pharma Patent 20,000 IU and the Vigantol 20,000 IU oral drops solutions and assessment of bioavailability in healthy volunteers

Healthy volunteers
Pharma Patent Kft.
36 participants planned
Hungary
2026-526224-48-02 on CTIS ↗
Phase I Not possible to specify Authorised 17/07/2026

A single center, randomized, controlled trial in healthy volunteers using dermal open flow microperfusion to assess cutaneous BE of two doxepin hydrochloride creams

No medical condition is being investigated in this clinical trial.
Medical University Of Graz
24 participants planned
Austria
2026-526078-18-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 17/07/2026

A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes

Type 1 Diabetes
Immunocore Limited
20 participants planned
Austria
2025-524449-28-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 17/07/2026

An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension due to Interstitial Lung Disease

Pulmonary hypertension secondary to interstitial lung disease
Tectonic Operating Company Inc.
9 participants planned
Poland · Romania · Spain
2026-525810-80-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 17/07/2026

Bioequivalence clinical trial of two formulations of dapagliflozin/metformin

Healthy participants
Laboratorios Alter S.A.
36 participants planned
Spain
2026-527164-32-00 on CTIS ↗
Phase II Otorhinolaryngologic Diseases Authorised 17/07/2026

Tolerability and efficacy of treating locally advanced Resectable Oral Cancer with neoadjuvant INtratumoral anti-CTLA4 ImmunoTherapy combined with systemic anti-PD-1 (ROCinIT).

Oral cavity squamous cell carcinoma
Amsterdam UMC Stichting
24 participants planned
Netherlands
2025-523617-29-01 on CTIS ↗
Phase III Female Urogenital Diseases and Pregnancy Complications Authorised 17/07/2026

Paracervical block with ropivacaine for pain relief in second trimester medical abortion - a double blind placebo controlled randomized trial

abortion
Karolinska Institutet
132 participants planned
Sweden
2025-524599-52-03 on CTIS ↗
Phase III Male Urogenital Diseases Authorised 16/07/2026

FOSFORMEN : Randomized, multicenter, non-inferiority trial comparing the efficacy of fosfomycin versus fluoroquinolones or cotrimoxazole as oral follow-up treatment in febrile urinary tract infections in men caused by susceptible enterobacteria

Febrile male urinary tract infections caused by Escherichia coli
Assistance Publique Hopitaux De Paris
312 participants planned
France
2026-525972-25-00 on CTIS ↗
Phase II Neoplasms Authorised 16/07/2026

PITALC. Pilot study on the effect of PITAC (Pressurized IntraThoracic Aerosol Chemotherapy) by videothoracoscopy in patients with malignant pleural effusion in the light of the results of a retrospective historical cohort treated with talc pleurodesis by videothoracoscopy

neoplastic pleural effusion
Hospices Civils De Lyon
20 participants planned
France
2025-523482-23-00 on CTIS ↗
Phase III Not possible to specify Authorised 16/07/2026

PROPHY-SEIN - Evaluation of the effect of antibiotic prophylaxis during lumpectomy for breast cancer: prospective randomised double-blind noninferiority study of placebo vs cefazolin

Breast Cancer
University Hospital Of Clermont-Ferrand
1600 participants planned
France
2025-525020-99-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 16/07/2026

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Confirm Efficacy and Safety of MH002 and to Assess the Effect of Dose in Patients With Mild-to-Moderate Ulcerative Colitis Insufficiently Controlled With 5-Aminosalicylic Acid

Ulcerative Colitis
Microbial Resource Management Health
109 participants planned
Czechia · Poland · Italy
2025-524682-24-00 on CTIS ↗
Phase I Skin and Connective Tissue Diseases Authorised 16/07/2026

A double-blind, randomised, placebo-controlled first-in-human/Phase Ib trial to investigate safety, tolerability, pharmacokinetics, and preliminary efficacy of single and multiple doses of TIR-C 2% cutaneous emulsion in adults with mild to moderate atopic dermatitis

Atopic dermatitis
Pharmability AB
52 participants planned
Sweden
2026-526343-35-00 on CTIS ↗
Phase II Otorhinolaryngologic Diseases Authorised 16/07/2026

Randomized, observer-blind, placebo-controlled, four Parallel Group, Clinical Trial for exploring the Efficacy and Tolerability of two different strengths ketotifen nasal spray (Ketotifen 0.025 mcg/ml and 0.050 mcg/ml) vs sodium cromoglicate nasal spray 2% in Patients with Rhinitis

Rhinitis
Eudemus Pharmaceuticals Limited
120 participants planned
Greece
2026-525419-16-00 on CTIS ↗
Phase II Pathological Conditions, Signs and Symptoms Authorised 15/07/2026

Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy: a phase II trial (OBLUMEN)

systemic lupus erythematosus pure membranous nephropathy
Assistance Publique Hopitaux De Paris
65 participants planned
France
2024-519985-35-00 on CTIS ↗
Phase II Not possible to specify Authorised 15/07/2026

COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial

Colorectal cancer with peritoneal metastases
Uppsala University Hospital
60 participants planned
Sweden
2026-526122-41-00 on CTIS ↗
Phase I/II Neoplasms Authorised 15/07/2026

Phase I/II clinical trial on the use of central nervous system administrations of CART-NKG2D or NKIL15 cells in children, adolescent and young adults with recurrent/refractory high grade Central Nervous System tumours (CINK-CAR)

Central nervous system tumours
Hospital Universitario La Paz
30 participants planned
Spain
2026-525876-24-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 14/07/2026

The MODIFY Study: A Phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on exacerbation rate, clinical remission, lung function decline, and safety in adults and adolescents with at risk Type 2 asthma, conducted up to 156 weeks.

Asthma
Glaxosmithkline Research & Development Limited
229 participants planned
Ireland · Spain · Germany · Czechia · Bulgaria · France · Belgium · Romania · Italy
2025-524463-20-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 14/07/2026

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke

Acute Ischemic Stroke
Takeda Development Center Americas Inc.
67 participants planned
Greece · Belgium · France · Germany
2025-522734-31-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 14/07/2026

Early TRIPLE versus dual LIPID lowering treatment in peOple with atherosclerotic cardiovascular disease and hypercholesterolemia Undergoing elecTive revascularisation - The randomized, controlled, open-label, parallel group TRIPLE-LIPID-OUT trial

Peripheral arterial disease, Coronary artery atherosclerotic heart disease, Hypercholesterolaemia
Medical University Of Graz
160 participants planned
Germany · Austria
2026-525917-29-00 on CTIS ↗
Phase III Neoplasms Authorised 14/07/2026

A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Metastatic colorectal cancer
Merck Healthcare KGaA
323 participants planned
Belgium · Germany · France · Denmark · Poland · Spain · Netherlands · Italy · Austria
2025-524648-37-00 on CTIS ↗
Phase I/II Hemic and Lymphatic Diseases Authorised 14/07/2026

FLAsH-IV-AML: A phase I/II multi-center study to assess the tolerability and efficacy of the addition of hydroxyurea to salvage treatment with fludarabine, ara-C, idarubicin and venetoclax for adults with relapsed or refractory acute myeloid leukemia

Adults (≥ 18 years of age) with relapsed or refractory acute myeloid leukemia (R/R AML)
Karolinska University Hospital
26 participants planned
Sweden
2026-526961-76-00 on CTIS ↗
Phase II Neoplasms Authorised 14/07/2026

A Phase II, Open-Label, Single-Arm, Multicentre Study of Immunotherapy and non-invasive response evaluation in cutaneous squamous cell carcinoma as an organ preservation strategy: a proof of concept clinical study and translational correlates - INCEPT

cutaneous squamous cell carcinoma
Fondazione GONO Plus
33 participants planned
Italy
2025-523633-25-00 on CTIS ↗
Phase III Female Urogenital Diseases and Pregnancy Complications Authorised 14/07/2026

A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS)
Apellis Pharmaceuticals Inc.
97 participants planned
France · Portugal · Spain · Slovakia · Italy · Germany · Poland
2025-524448-36-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 14/07/2026

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma

Metastatic Pancreatic Adenocarcinoma
Revolution Medicines Inc.
337 participants planned
Poland · Belgium · Norway · Sweden · Austria · Germany · Denmark · Netherlands · France · Italy · Spain
2025-525088-34-00 on CTIS ↗
Phase I Not possible to specify Authorised 14/07/2026

An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (¹⁷⁷Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC)

Metastatic triple negative breast cancer
Universitaetsklinikum Aachen AöR
18 participants planned
Germany
2025-524027-49-00 on CTIS ↗
Phase IV Female Urogenital Diseases and Pregnancy Complications Authorised 14/07/2026

Efficacy of oral bicarbonate versus placebo on the risk of assisted delivery in nulliparous women with prolonged labour (ProLabour): protocol fora randomized controlled trial

Prolonged labour
Region Hovedstaden
1520 participants planned
Denmark
2026-525682-45-00 on CTIS ↗
Phase II Immune System Diseases Authorised 13/07/2026

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease

Antibody-mediated Kidney Disease
AstraZeneca AB
17 participants planned
France · Germany · Italy · Belgium · Poland · Spain
2025-524139-38-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 13/07/2026

Model-informed precision dosing for linezolid: a randomized clinical trial

Bacterial infection (pneumonia, skin or soft tissue infection) requiring treatment with linezolid in patients in intensive care unit
University Medical Center Hamburg-Eppendorf
30 participants planned
Germany
2024-517888-23-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 13/07/2026

Phase II, Multicenter, Randomized Study to Evaluate Safety and Efficacy of MRD-guided Therapy with Reduced versus Standard Dose of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (REBEL)

Relapsed/refractory Multiple myeloma
Polish Myeloma Consortium
228 participants planned
Poland
2025-525096-83-00 on CTIS ↗
Phase I/II Neoplasms Authorised 13/07/2026

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma

Multiple Myeloma (MM), Multiple Myeloma (MM)
AbbVie Deutschland GmbH & Co. KG
88 participants planned
Germany · Poland · Czechia · Belgium · France · Greece · Sweden · Portugal · Italy
2025-525105-20-00 on CTIS ↗
Phase II Immune System Diseases Authorised 13/07/2026

Inducing durable immunological control of HIV-1 through administration of long-acting broadly neutralizing antibodies and low-dose anti-PD-1 – a randomized, double-blinded, placebo-controlled trial (the IDUNN trial)

HIV-1 disease
Region Midtjylland
60 participants planned
Sweden · Norway · Denmark · Iceland
2025-523725-17-00 on CTIS ↗
Phase II Neoplasms Authorised 13/07/2026

A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)

Familial Adenomatous Polyposis
Recursion Pharmaceuticals Inc.
20 participants planned
Netherlands · Germany · Spain
2026-525282-50-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 13/07/2026

SUNCET: Low sodium oxybate Use for Nocturnal Cluster headache: safety, Efficacy and Tolerability of XYWAV - a Phase 2 Randomized, Double-Blind, Placebo-Controlled, bi-center Study

Cluster headache
Leids Universitair Medisch Centrum (LUMC)
26 participants planned
Netherlands
2025-523293-17-00 on CTIS ↗
Phase IV Reproductive and Urinary Physiological Phenomena Authorised 13/07/2026

Phase IV randomized, single-blind clinical trial with three parallel arms to compare ovulation triggering strategies in IVF cycles with fresh embryo transfer.

Women with infertility and low ovarian reserve.
Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA
126 participants planned
Spain
2026-526292-37-01 on CTIS ↗
Phase I Neoplasms Authorised 13/07/2026

A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

Relapsed or Refractory acute myeloid leukemia, Relapsed or Refractory chronic lymphocytic leukemia, Relapsed or Refractory higher-risk myelodysplastic syndromes, Relapsed or Refractory small lymphocytic lymphoma
Janssen Cilag International
175 participants planned
France · Spain · Germany · Denmark · Belgium
2026-525234-39-00 on CTIS ↗
Phase II Virus Diseases Authorised 13/07/2026

Achieving viral CLEARance in immunocompromised participants with long-term persistence of SARS-CoV-2 - an open-label randomized trial (CLEAR)

Long-term persistence of SARS-CoV-2
Goethe University Frankfurt
24 participants planned
Germany · Spain
2025-524442-10-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 10/07/2026

Effect of Vitamin D supplementation on MyocardIal Fibrosis in PaTients with Acute Myocarditis (EDIT-AM): a multicenter, open-label, randomized controlled trial

Myocardial fibrosis, Acute myocarditis
Spanish Society Of Cardiology
152 participants planned
Spain
2025-523092-33-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 10/07/2026

A Randomized, Placebo-controlled, Double-blind, Dose-finding Phase 1b Study to Assess the Safety, Immunogenicity and Pharmacodynamics of TRB-001 in Early Idiopathic Parkinson’s Disease Patients

Parkinson's disease
Tridem Bioscience FlexCo
18 participants planned
Austria
2024-519123-14-00 on CTIS ↗
Phase II Female Urogenital Diseases and Pregnancy Complications Authorised 10/07/2026

Prospective trial of [18F]AlF-FAPI-74 for PET imaging of fibroblast activation protein in patients with endometriosis

endometriosis
UZ Leuven
64 participants planned
Belgium
2026-525272-25-00 on CTIS ↗
Phase I Cardiovascular Diseases Authorised 10/07/2026

A Phase 1, Randomized, Placebo-Controlled, Multiple-Dose, Dose-Ranging Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTX611 in Healthy Adult Participants

Thromboembolic disorders
CRISPR Therapeutics AG
48 participants planned
Hungary
2026-526708-56-00 on CTIS ↗
Phase I/II Neoplasms Authorised 10/07/2026

EXUROC Bladder Target - A phase Ib/ll study to determine the safety, tolerability, and efficacy of LP-184 treatment in patients with advanced/metastatic urothelial carcinoma

Oncology
Region Hovedstaden
39 participants planned
Denmark
2026-525808-94-00 on CTIS ↗
Phase I Hormonal diseases Authorised 10/07/2026

A study to learn how a high-fat meal affects the way elinzanetant is taken up by the body in healthy women

Vasomotor symptoms as a sex hormone-dependent disorder in women and men
Bayer AG
30 participants planned
Germany
2026-525569-30-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 10/07/2026

Preventing urinary tract infections in infants and young children with probiotic E. coli Nissle: FinNissle randomized controlled trial

Urinary tract infection or Pyelonephritis
Pohjois-Pohjanmaan hyvinvointialue
250 participants planned
Finland
2026-526444-13-01 on CTIS ↗
Phase II Neoplasms Authorised 09/07/2026

A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement

Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement
Elevar Therapeutics Inc.
14 participants planned
France · Spain
2025-523923-22-00 on CTIS ↗
Phase III Neoplasms Authorised 09/07/2026

AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

acute lymphoblastic leukemia in children and adolescents
Universitaetsklinikum Schleswig-Holstein AöR
2250 participants planned
Germany
2025-522190-11-01 on CTIS ↗
Phase II Neoplasms Authorised 09/07/2026

Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in MESOthelioma

Pleural mesothelioma
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
42 participants planned
Netherlands
2026-526036-38-00 on CTIS ↗
Phase IV Musculoskeletal Diseases Authorised 09/07/2026

Early switch to oral antibiotic therapy in vertebral osteomyelitis: a multicentre, open-label, randomised, active control, parallel group, non-inferiority trial (sWITCH-VO)

bone and joint infections
University Of Cologne
280 participants planned
Germany
2026-526270-17-00 on CTIS ↗
Phase II Immune System Diseases Authorised 08/07/2026

Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 2 to Master Protocol ARGX-999-2-MG-2000 – an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
Argenx
29 participants planned
Greece · Italy · Germany · Belgium · Netherlands · Spain · Poland
2025-522939-33-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 08/07/2026

Open-label, single-center, single-arm phase 2 futility trial evaluating the oral indapamide for reducing progression of disability in people with primary and secondary progressive multiple sclerosis (MS)

Multiple Sclerosis
Amsterdam UMC Stichting
84 participants planned
Netherlands
2026-525260-18-00 on CTIS ↗
Phase III Eye Diseases Authorised 08/07/2026

A multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy (Beltavac®) with Polymerized Allergenic Extract of a Mixture of Dermatophagoides and Blomia tropicalis in Patients with Allergic Rhinitis/rhinoconjunctivitis.

Allergic rhinitis/rhinoconjunctivitis due to house dust mites exposure
Probelte Pharma S.L.
174 participants planned
Spain
2026-526105-15-00 on CTIS ↗
Phase I Bacterial Infections and Mycoses Authorised 08/07/2026

Nasal application of Staphylococcus lugdunensis for decolonization of Staphylococcus aureus – a first-in-human proof-of-concept microbiome intervention study

Persistent or intermitting colonization of the nose with Staphylococcus aureus
Universitaetsklinikum Tuebingen AöR
36 participants planned
Germany
2024-514894-22-01 on CTIS ↗
Phase III Neoplasms Authorised 08/07/2026

Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

Osteosarcoma
Institut Gustave Roussy
508 participants planned
Sweden · Poland · Denmark · Finland · Netherlands · Italy · France · Spain
2023-505575-69-01 on CTIS ↗
Phase II Nervous System Diseases Authorised 08/07/2026

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults with Narcolepsy

Narcolepsy
Eisai Limited
51 participants planned
Belgium · Italy · Spain · Germany
2025-523503-30-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 08/07/2026

HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Female Patients with Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)

Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)
Alnylam Pharmaceuticals Inc.
5 participants planned
Netherlands · Sweden · Germany
2025-524967-19-00 on CTIS ↗
Phase I Not possible to specify Authorised 08/07/2026

A study to compare how 2 different formulations of survodutide are taken up in the body when given by injection in healthy men and women with and without overweight or obesity

Healthy
Boehringer Ingelheim International GmbH
44 participants planned
Germany
2026-526307-30-00 on CTIS ↗
Phase I Virus Diseases Authorised 07/07/2026

A Trial to Evaluate the Safety and Drug Levels of Single and Multiple Oral Doses of AT-587 in Healthy Adults

Chronic hepatitis E virus (HEV) infection
Atea Pharmaceuticals Inc.
62 participants planned
Belgium
2026-526237-26-00 on CTIS ↗
Phase I Digestive System Diseases Authorised 07/07/2026

A clinical trial comparing how the body takes up budesonide from different forms of medicine when taken by mouth with or without food.

Acute eosinophilic esophagitis
Dr. Falk Pharma GmbH
50 participants planned
Sweden
2025-522686-29-00 on CTIS ↗
Phase I Bacterial Infections and Mycoses Authorised 07/07/2026

Phase I Safety and Immunogenicity Study of a Multivalent Gonorrhoea Vaccine

Gonorrhea
LimmaTech Biologics AG
142 participants planned
Germany
2026-526168-19-00 on CTIS ↗
Phase II Neoplasms Authorised 07/07/2026

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion

Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion
Bristol-Myers Squibb Services Unlimited Company
123 participants planned
Belgium · Ireland · Germany · Norway · Italy · France · Spain
2025-524285-18-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 07/07/2026

An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Xembify versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Grifols Therapeutics LLC
20 participants planned
Romania · Czechia · Poland
2025-522165-30-00 on CTIS ↗
Phase III Eye Diseases Authorised 07/07/2026

Multicenter, randomized, double-blind, parallel-group clinical study comparing RD03/2016 (levoFloxacin and ketorolac trometAmol) eye drops vs Leviosa® (levofloxacin and dexamethaSone 21-phosphaTe) eye drops for 7 days for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults. (FAST 7)

Cataract
Ntc S.r.l.
536 participants planned
Spain · Poland · Greece · Sweden · Italy
2026-525594-39-00 on CTIS ↗
Phase I Neoplasms Authorised 07/07/2026

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (FiREBOLT)

Ovarian Neoplasms Breast Neoplasms Pancreatic Intraductal Neoplasms Colorectal Neoplasms Esophageal Neoplasms Stomach Neoplasms Cholangiocarcinoma
Eli Lilly & Co.
64 participants planned
Germany · Netherlands
2025-521887-37-00 on CTIS ↗
Phase I/II Nutritional and Metabolic Diseases Authorised 07/07/2026

A PHASE 1/2 STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFECTS ON CLINICAL OUTCOMES OF PEGTIBATINASE (TVT-058) ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH CYSTATHIONINE BETASYNTHASE-DEFICIENT HOMOCYSTINURIA (COMPOSE)

Classical Homocystinuria
Travere Therapeutics Switzerland GmbH, Travere Therapeutics Inc.
6 participants planned
France
2023-509074-31-00 on CTIS ↗
Phase III Neoplasms Authorised 07/07/2026

C6461016 - A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
Pfizer Inc.
91 participants planned
France · Spain · Italy
2025-524717-86-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 07/07/2026

A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B)

Fibrosing interstitial lung disease
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
20 participants planned
Belgium · Greece · Germany · France · Finland · Spain · Czechia · Poland · Italy · Netherlands · Denmark · Portugal
2025-523369-32-00 on CTIS ↗
Phase III Neoplasms Authorised 07/07/2026

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Multiple Myeloma who Have Received One to Three Prior Lines of Therapy

Multiple Myeloma
F. Hoffmann-La Roche AG
133 participants planned
France · Germany · Italy · Greece · Denmark · Czechia · Spain · Poland
2025-524028-23-00 on CTIS ↗
Phase III Neoplasms Authorised 06/07/2026

Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288

Metastatic Pancreatic Ductal Adenocarcinoma; PDAC
AbbVie Deutschland GmbH & Co. KG
194 participants planned
Portugal · Spain · France · Italy · Germany · Austria
2025-522563-15-00 on CTIS ↗
Phase III Neoplasms Authorised 06/07/2026

TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer

Patients with advanced or metastatic ER+ HER2- breast cancer
Unicancer
526 participants planned
France
2025-524213-84-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 06/07/2026

Macroleave: Impact of discontinuation of long-term macrolides in stable Non Cystic Fibrosis Bronchiectasis : a multicenter randomized controlled trial

bronchiectasis unrelated to cystic fibrosis
Centre Hospitalier Intercommunal Creteil
185 participants planned
France
2025-521493-33-00 on CTIS ↗
Phase II Surgical Procedures, Operative Authorised 06/07/2026

Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant recipients: A phase 2 trial RSVaxID

allogeneic haematopoietic stem cell transplant recipient, lung transplant
Hospices Civils De Lyon
400 participants planned
France
2025-524374-42-00 on CTIS ↗
Phase II Therapeutics Authorised 06/07/2026

Shared decision-making in uncomplicated appendicitis: a pragmatic randomized trial comparing patient-driven choice (antibiotics only or appendectomy) with systematic appendectomy (FRENCH 47 — ALACARTE trial)

Adult patients diagnosed with uncomplicated acute appendicitis
Assistance Publique Hopitaux De Paris
560 participants planned
France
2025-520783-17-01 on CTIS ↗
Phase II Neoplasms Authorised 06/07/2026

Feasibility of fluorescence imaging with bevacizumab-800CW during bronchoscopy in patients with a pulmonary lesion considered to be malignant - DFLECT I

suspected malignant pulmonary disease (lung lesions and/or lymph nodes suspicious for lung cancer)
Universitair Medisch Centrum Groningen
20 participants planned
Netherlands
2024-510793-24-00 on CTIS ↗
Phase I Bacterial Infections and Mycoses Authorised 06/07/2026

A study to investigate the repeat-dose pharmacokinetics of a combined oral contraceptive when given alone and in combination with ganfeborole in female participants of non-childbearing potential.

Tuberculosis
Glaxosmithkline Research & Development Limited
28 participants planned
Spain
2026-525790-39-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 06/07/2026

Oral versus Intravenous Tranexamic Acid for Blood Loss Prevention in Off-Pump Coronary Artery Bypass Surgery: A Randomised Non-Inferiority Trial (TRANSCAB Study)

Coronary artery disease requiring off-pump coronary artery bypass surgery (OPCAB)
Sante et Prevoyance
160 participants planned
Belgium
2026-526581-24-01 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 06/07/2026

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement
613 participants planned
Denmark · Sweden · Poland · Estonia · Portugal · Latvia · Spain · Hungary · Germany · Finland · Italy · Belgium · France
2024-518016-39-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 06/07/2026

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement
550 participants planned
Germany · Romania · Greece · Norway · Netherlands · Poland · Lithuania · Czechia · Slovakia · Spain
2024-518213-25-00 on CTIS ↗
Phase I Neoplasms Authorised 06/07/2026

A Phase 1 Study of TORL-1-23 in Advanced Cancer

Advanced Cancer
Torl Biotherapeutics LLC
12 participants planned
Ireland
2024-517189-40-00 on CTIS ↗
Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 06/07/2026

iSTOP-CP: intranasal Stem Cells to treat Perinatal brain injury to combat Cerebral Palsy

Hypoxic-ischemic brain injury (HIBI) because of Perinatal Asphyxia (PA) or Perinatal arterial ischemic stroke (PAIS)
Universitair Medisch Centrum Utrecht
162 participants planned
Netherlands
2025-521506-17-01 on CTIS ↗
Phase IV Digestive System Diseases Authorised 06/07/2026

Efficacy, Safety, and Patient Satisfaction of Patient-Controlled Remimazolam Sedation in Outpatient Colonoscopy: A randomized controlled trial.

The trial will study sedation related to colonoscopy, therefore the trial is not concerned with the underlaying medical condition leading to the colonoscopy.
Region Hovedstaden
1 participants planned
Denmark
2026-525809-13-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 06/07/2026

The RELEASE Trial: Reconsidering Long-Term Aspirin in the Elderly in Secondary Prevention of Cardiovascular Disease

Ischemic heart disease/Chronic coronary syndrome (Myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting)
Odense University Hospital
7000 participants planned
Denmark
2026-525442-30-00 on CTIS ↗
Phase IV Musculoskeletal Diseases Authorised 06/07/2026

Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference

Rheumatoid arthritis
Aalborg University Hospital, Aalborg University Hospital
180 participants planned
Denmark
2026-525221-21-01 on CTIS ↗
Phase I/II Neoplasms Authorised 03/07/2026

A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination with mFOLFOX6 or FOLFIRI in Patients with Solid Tumors

Solid tumors
Larkspur Biosciences Inc.
80 participants planned
France
2026-525629-20-00 on CTIS ↗
Phase I Hemic and Lymphatic Diseases Authorised 03/07/2026

Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants with End-Stage Kidney Disease on Hemodialysis

End-Stage Kidney Disease (ESKD)
Regeneron Pharmaceuticals Inc.
36 participants planned
Belgium
2026-525844-14-00 on CTIS ↗
Phase II Mental Disorders Authorised 03/07/2026

The Acute and Long-term Impact of Support in Psilocybin Therapy for Depression: The Psilocybin Setting Trial (PSISET)

Depression
Kobenhavns Universitet, Koebenhavns Universitet
180 participants planned
Denmark
2025-522961-31-01 on CTIS ↗
Phase II Neoplasms Authorised 03/07/2026

Individualized Intrathecal Chemotherapy Based on Measurement of Brain Fluid Clearance in Pediatric Patients

Acute lymphoblastic leukemia and lymphoma
Oslo University Hospital HF
50 participants planned
Norway
2025-522453-20-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 03/07/2026

Dual-agent fluorescence-guided surgery for colorectal liver metastases

Colorectal liver metastases
Leids Universitair Medisch Centrum (LUMC)
39 participants planned
Netherlands
2025-524755-31-00 on CTIS ↗
Phase II Psychological Phenomena Authorised 03/07/2026

A Randomized, Delayed-Treatment Controlled, Phase 2 Pilot Study of Manualized MDMA-Assisted Therapy for Young Adults with Chronic Treatment-Resistant Major Depressive Disorder

Major Depressive Disorder
Ostfold Hospital Trust
16 participants planned
Norway
2024-520319-42-01 on CTIS ↗
Phase I Female Urogenital Diseases and Pregnancy Complications Authorised 03/07/2026

Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial - The CALCIFER Trial

Bladder cancer, Bladder tumors, Urothelial cancer, Urothelial tumors
Region Sjaelland
20 participants planned
Denmark
2026-526388-39-00 on CTIS ↗
Phase II Neoplasms Authorised 03/07/2026

A multicenter open-label phase II study of Cemiplimab plus chemotherapy, selected on the basis of baseline cytidine deaminase activity, in advanced squamous non-small cell lung cancer - CECYDE trial - GOIRC-04-2024

Advanced squamous non-small cell lung cancer
G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica
108 participants planned
Italy
2024-517799-40-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 02/07/2026

Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment

myeloproliferative neoplasms
Centre Hospitalier Regional Et Universitaire De Brest
50 participants planned
France
2025-523921-17-00 on CTIS ↗
Phase II Diagnosis Authorised 02/07/2026

18F-fluoro-ethyl-tyrosine (18FET) PET for difficult clinical situations in functional pituitary adenoma. A prospective, single arm, single center study. (FET-PIT)

Patients (male or female) ≥18 years old with Suspected functional pituitary adenoma (prolactinoma, Cushing's disease, acromegaly, thyrotropic adenoma), de novo or recurrence/persistence, With indeterminate pituitary MRI.
Centre Hospitalier Universitaire De Lille
30 participants planned
France
2025-523829-17-00 on CTIS ↗
Phase I Cardiovascular Diseases Authorised 02/07/2026

Bioequivalence Study of Dapagliflozin 10 mg

Not applicable (submitted trial is a BE study in healthy participants)
Vipharm S.A.
40 participants planned
Czechia
2026-526840-10-00 on CTIS ↗
Phase II Neoplasms Authorised 02/07/2026

IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer

Stage III Non Small Cell Lung Cancer
Intergroupe Francophone De Cancerologie Thoracique
177 participants planned
France
2025-522801-39-00 on CTIS ↗
Phase I Neoplasms Authorised 02/07/2026

Network pharmacology-based personalized drug repurposing in thyroid carcinoma: a pilot feasibility trial

Advanced thyroid cancer
Stichting Radboud University Medical Center
10 participants planned
Netherlands
2023-507214-28-00 on CTIS ↗
Phase III Mental Disorders Authorised 01/07/2026

AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial)

First Episode Psychosis (FEP)
University Of Oxford
156 participants planned
Netherlands · Greece · Germany · Italy · Austria · Spain
2025-521929-32-01 on CTIS ↗
Phase I/II Neoplasms Authorised 01/07/2026

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer

DLL3 Expressing Tumors Including Small Cell Lung Cancer
Ideaya Biosciences Inc.
35 participants planned
France · Spain
2025-523438-24-00 on CTIS ↗
Phase III Neoplasms Authorised 01/07/2026

"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide"

Relapsed or Refractory Multiple Myeloma
Janssen Cilag International
206 participants planned
Poland · Spain · Czechia · France · Italy · Germany · Greece
2025-523815-12-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 01/07/2026

High-dose Insulin Euglycemic Therapy in Non-Toxic Acute Cardiogenic Shock.

Non-toxic acute cardiogenic shock
Oslo Universitetssykehus HF
20 participants planned
Norway
2025-523858-13-01 on CTIS ↗
Phase I Skin and Connective Tissue Diseases Authorised 01/07/2026

A phase 1b trial to study the safety and effect of ZP9830 in patients with plaque psoriasis

Plaque Psoriasis
Zealand Pharma A/S
32 participants planned
Netherlands
2026-525220-15-00 on CTIS ↗
Phase I Immune System Diseases Authorised 01/07/2026

An open label, balanced, randomized, single dose, two-treatment, two period, two-sequence, crossover, bioequivalence study comparing Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablet 180 mg/240 mg, Manufactured by: Sun Pharmaceutical Industries Limited, India with Allegra-D® 24 HR (Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablets 180 mg + 240 mg) tablets, Distributed by: Chattem Inc., a Sanofi Company Chattanooga, TN 37409-0219, USA, in healthy, adult, human participants under fed conditions.

Seasonal allergic rhinitis
Sun Pharmaceutical Industries Limited
48 participants planned
Romania
2026-525421-20-00 on CTIS ↗
Phase I Immune System Diseases Authorised 01/07/2026

An open label, balanced, randomized, single dose, two-treatment, four period, two-sequence, crossover, fully replicate, bioequivalence study comparing Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablet USP 180 mg/240 mg, Manufactured by: Sun Pharmaceutical Industries Limited, India with Allegra-D® 24 HR (Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablets 180 mg + 240 mg) tablets, Distributed by: Chattem Inc., a Sanofi Company Chattanooga, TN 37409-0219, USA, in healthy, adult, human participants under fasting conditions.

Seasonal allergic rhinitis
Sun Pharmaceutical Industries Limited
48 participants planned
Romania
2026-525420-22-00 on CTIS ↗
Phase I/II Nervous System Diseases Authorised 01/07/2026

The headache- and migraine-inducing effects of apremilast in women with migraine without aura

Migraine without aura
Syddansk Universitet (University of Southern Denmark)
14 participants planned
Denmark
2026-525987-16-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 01/07/2026

A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose‑ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) versus Placebo in Participants of 4 to Less than 12 Years of Age with Asthma Receiving Background Budesonide and Formoterol Fumarate (BFF) (FAROS)

Asthma
AstraZeneca AB
35 participants planned
Czechia · Poland · Hungary
2025-524914-26-00 on CTIS ↗
Phase I Immune System Diseases Authorised 01/07/2026

A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis

Rheumatoid Arthritis
AbbVie Deutschland GmbH & Co. KG
19 participants planned
Belgium · Netherlands · Spain · Germany · Italy
2025-523127-21-00 on CTIS ↗
Phase I Not possible to specify Authorised 01/07/2026

A study in healthy men to find out how blocking certain transport proteins affects the amount of BI 3000202 in the blood

Healthy
Boehringer Ingelheim International GmbH
16 participants planned
Germany
2026-525549-60-00 on CTIS ↗
Phase III Neoplasms Authorised 01/07/2026

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
Genmab A/S
257 participants planned
Finland · Belgium · Hungary · France · Denmark · Austria · Germany · Italy · Spain · Czechia · Norway · Poland
2025-522167-15-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 01/07/2026

C6501003 - A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study to Assess Relative Bioavailability of PF-08653945 When Administered Across Different Injection Sites in Adults With Overweight or Obesity

chronic weight management and other weight-related co-morbidities
Pfizer Inc.
57 participants planned
Belgium
2026-526334-67-00 on CTIS ↗
Phase I Not possible to specify Authorised 30/06/2026

A study in healthy men to test how BI 1815368 is processed in the body

Healthy volunteers trial
Boehringer Ingelheim International GmbH
8 participants planned
Netherlands
2025-523949-10-00 on CTIS ↗
Phase IV Reproductive and Urinary Physiological Phenomena Authorised 30/06/2026

Progesterone Luteal Support in Unexplained Infertility Management (PLUIM study)

unexplained subfertillity, infertillity
Universitair Medisch Centrum Utrecht
640 participants planned
Netherlands
2026-525747-33-00 on CTIS ↗
Phase I Physiological processes Authorised 30/06/2026

Evaluation of bioequivalence of two products containing estradiol: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA 0.1% gel (Comparator). An open, randomized, single-dose, four-period, full-replicative trial in healthy postmenopausal women

No therapeutic indication in the current trial with healthy volunteers.
CCDRD Cooperative Clinical Drug Research and Development AG, Ioulia And Irene Tseti Pharmaceutical Laboratories S.A.
140 participants planned
Bulgaria
2025-524775-23-00 on CTIS ↗
Phase I/II Neoplasms Authorised 30/06/2026

A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

solid tumor
Krystal Biotech Inc.
40 participants planned
France · Spain
2025-522723-98-00 on CTIS ↗
Phase III Immune System Diseases Authorised 30/06/2026

Phase III, Open-label Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, Efficacy, and Immunogenicity of Benralizumab in Children with Eosinophilic Disease (CLIPS)

Eosinophilic Disease
AstraZeneca AB
7 participants planned
Poland · Netherlands · France
2023-508533-14-00 on CTIS ↗
Phase II Neoplasms Authorised 30/06/2026

A phase IIa, single-arm, single-center, open label, proof-of-concept trial evaluating increased frequency dosing of VCN-01 (zabilugene almadenorepvec) in combination with nab-Paclitaxel/Gemcitabine (GnP) in Patients with Newly-Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)

metastatic pancreatic adecarcinoma
Theriva Biologics S.L.
6 participants planned
Spain
2026-525566-21-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 30/06/2026

A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection

Non Small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc.
45 participants planned
Spain · Belgium · France · Italy · Germany
2025-521971-29-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 30/06/2026

A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Pulmonary Hypertension Associated with Interstitial Lung Disease
Insmed Inc.
165 participants planned
Greece · France · Italy · Belgium · Denmark · Germany · Poland · Czechia · Portugal · Austria · Spain · Romania
2025-521769-29-00 on CTIS ↗
Phase I/II Nervous System Diseases Authorised 30/06/2026

Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome

Dravet Syndrome
Ionis Pharmaceuticals Inc.
11 participants planned
Spain · France · Belgium · Portugal · Germany
2025-523835-20-00 on CTIS ↗
Phase I Skin and Connective Tissue Diseases Authorised 30/06/2026

A double-blind, prospective, randomised, placebo-controlled, single-centre, proof-of-principle trial in healthy volunteers to investigate safety, local tolerability, pharmacokinetics, and pharmacodynamics of Asacaine after topical administration on skin exposed to ultraviolet B radiation

Topical pain
Auxesis Pharma Holding AB (publ)
12 participants planned
Sweden
2026-526022-41-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 30/06/2026

Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci

Infectious endocarditis caused by Gram-positive cocci (staphylococci, enterococci, streptococci)
Friedrich-Schiller-Universitaet Jena
166 participants planned
Germany
2026-526149-91-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 30/06/2026

A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma

Participants with relapsed HRNB and participants with HRNB refractory to treatment The clinical trial will recruit participants aged ≥18 months to <18 years, and therefore all participants will be minors at the time of consent.
Renaissance Pharma Limited
111 participants planned
France · Spain · Denmark · Ireland · Germany
2025-524397-42-00 on CTIS ↗
Phase I Not possible to specify Authorised 30/06/2026

A study to compare how the body absorbs 4 different forms of norucholic acid medicine (tablets, granules, and capsules) when taken with or without food in healthy adults

Not applicable, healthy volunteers
Dr. Falk Pharma GmbH
32 participants planned
Germany
2025-523778-17-00 on CTIS ↗
Phase I Not possible to specify Authorised 29/06/2026

A Phase 1 Randomized, Double-Blind, placebo-controlled, clinical study to evaluate safety and Pharmacokinetics, of Single Ascending Doses and Multiple Ascending Doses of AIK3a305 in Healthy Volunteers

Treatment of several inflammatory diseases, including inflammation-related fibrosis and autoinflammatory diseases
Allinky Biopharma S.L.
42 participants planned
Spain
2026-525830-49-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 29/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care

Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Merck Healthcare KGaA
57 participants planned
Germany · Romania · France · Bulgaria · Belgium · Spain · Poland · Greece · Italy · Czechia
2025-524855-30-00 on CTIS ↗
Phase III Immune System Diseases Authorised 29/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care

Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Merck Healthcare KGaA
54 participants planned
Spain · Belgium · France · Germany · Slovakia · Romania · Bulgaria · Italy · Poland · Greece
2025-523871-44-00 on CTIS ↗
Phase III Neoplasms Authorised 29/06/2026

AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer

Colorectal Cancer
AbbVie Deutschland GmbH & Co. KG
243 participants planned
Greece · Portugal · Germany · Belgium · Spain
2025-521712-19-00 on CTIS ↗
Phase III Not possible to specify Authorised 29/06/2026

Methoxyflurane versus Standard Care for Non-Traumatic Pain in the Emergency Department (PAIN-THROX) : A Multicenter, Randomized, Controlled, Superiority Trial

Non-traumatic pain
Centre Hospitalier Regional Universitaire De Tours
164 participants planned
France
2025-525001-21-00 on CTIS ↗
Phase II Neoplasms Authorised 29/06/2026

C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer

Small Cell Lung Cancer
Pfizer Inc.
15 participants planned
France · Italy · Spain
2025-524686-24-00 on CTIS ↗
Phase II Mental Disorders Authorised 29/06/2026

Randomised open-label pilot Study on Thiamine supplementation to REduce braiN injury associated with chronic Alcohol use in outpatients with alcohol use disorder : STRENA

Alcoholism
Institut National De La Sante Et De La Recherche Medicale
60 participants planned
France
2025-524148-36-00 on CTIS ↗
Phase IV Nutritional and Metabolic Diseases Authorised 29/06/2026

ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study)

Obstructive sleep apnea syndrome, Obesity
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre
345 participants planned
Spain
2026-525500-10-00 on CTIS ↗
Phase II Neoplasms Authorised 29/06/2026

A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)

Non-small Cell Lung Cancer
AstraZeneca AB
11 participants planned
Spain · Germany
2025-523599-21-00 on CTIS ↗
Phase I/II Respiratory Tract Diseases Authorised 29/06/2026

PET imaging For eaRly predictiOn of respoNse to neoadjuvanT tReatment in lUNg caNcER

Non small cell lung cancer
Radboud universitair medisch centrum Stichting
40 participants planned
Netherlands · Germany
2025-524791-30-00 on CTIS ↗
Phase I/II Neoplasms Authorised 29/06/2026

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors

Solid Tumors
Revolution Medicines Inc.
252 participants planned
France · Poland · Ireland · Spain · Greece · Germany · Italy · Sweden · Belgium
2025-524623-50-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 29/06/2026

CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL

Community- acquired pneumonia related sepsis with evidence of Sepsis Induced Immunoparalysis SII
Elliniko Institouto Meletis Tis Sipsis
252 participants planned
Greece
2025-525058-20-00 on CTIS ↗
Phase I Diagnosis Authorised 29/06/2026

LAFOV-Lung PET

Investigation in healthy volunteers
Medical University Of Vienna
41 participants planned
Austria
2026-525834-45-00 on CTIS ↗
Phase II Immune System Diseases Authorised 29/06/2026

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Mediar Therapeutics Inc.
36 participants planned
Netherlands · Romania · Poland · France · Italy · Spain
2025-523288-39-00 on CTIS ↗
Phase I Neoplasms Authorised 29/06/2026

First study evaluating the safety and dosage of YG-01 in patients with a malignant brain tumor

Glioblastoma
Ygion Biomedical GmbH
15 participants planned
Austria
2025-524299-44-00 on CTIS ↗
Phase III Female Urogenital Diseases and Pregnancy Complications Authorised 29/06/2026

A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants with Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer

Non-Muscle Invasive Papillary Bladder Cancer
Hamlet BioPharma AB
169 participants planned
Czechia
2026-525531-16-00 on CTIS ↗
Phase IV Mental Disorders Authorised 29/06/2026

Unprescribing the Pill to Reassess Symptom and Cognitive Recovery in Depression (UNPRESCRIB-D)

Major Depressive Disorder
Region Hovedstaden
106 participants planned
Denmark
2026-526314-90-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 28/06/2026

Self-Assessment Method for Statin side-effects Or Nocebo 2

Cardiovascular diseases
Copenhagen University Hospital, Region Hovedstaden
160 participants planned
Denmark
2025-524955-30-01 on CTIS ↗
Phase I Neoplasms Authorised 26/06/2026

A Phase 1 Study of BMS-986460 in Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb Services Unlimited Company
22 participants planned
France
2024-513987-24-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 26/06/2026

Randomized Evaluation of fleCAinide safety vs. STandard of care in patients with coronary artery disease and Atrial Fibrillation (ReCAST AF).

Coronary artery disease, Atrial fibrillation
UZ Leuven
988 participants planned
Belgium
2025-525121-13-00 on CTIS ↗
Phase IV Hormonal diseases Authorised 26/06/2026

Prospective, multicenter, randomized study on combined LT4 + LT3 therapy versus LT4 in the control of TSH in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors.

Advanced thyroid carcinoma. Post-thyroidectomy hypothyroidism.
Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l.
110 participants planned
Italy
2026-526113-28-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 26/06/2026

Three-part PK and PD study of AXN-027

Chronic pain, refractory epilepsy, and other neurological disorders of excitation/inhibition (E/I) imbalance within neuronal circuits.
Axonis Therapeutics Inc.
64 participants planned
Netherlands
2025-524019-35-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 26/06/2026

Short and long-term Hemodynamic and Physiological Effects of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy
Region Skane
40 participants planned
Sweden
2025-524722-17-00 on CTIS ↗
Phase II Disorders of Environmental Origin Authorised 26/06/2026

“In vivo” biological standardization of the allergenic extracts Dermatophagoides pteronyssinus (DPT) and Dermatophagoides farinae (DF) in patients sensitized to them.

IgE-mediated respiratory allergic disease due to the allergen whose extract is to be standardized, DPT and DF.
Probelte Pharma S.L.
30 participants planned
Spain
2026-525628-13-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 26/06/2026

A 2-Part, Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against Factor XI, for the Treatment and Secondary Prevention of Venous Thromboembolism in Participants with Solid and Hematologic Cancers (ROXI-CAT-II)

Cancer Associated Thrombosis
Regeneron Pharmaceuticals Inc.
164 participants planned
Bulgaria · Romania
2024-519299-16-00 on CTIS ↗
Phase I Mental Disorders Authorised 26/06/2026

Skin irritation and sensitization trial

The intended indication is for the treatment of major depressive disorder.
CCDRD Cooperative Clinical Drug Research and Development AG, Corium Innovations Inc.
230 participants planned
Bulgaria
2026-525269-34-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 26/06/2026

Colchicine after Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial

Atrial Fibrillation
Universitaetsspital Basel
1 participants planned
Germany
2024-516033-12-00 on CTIS ↗
Phase IV Hemic and Lymphatic Diseases Authorised 26/06/2026

Phase IV study evaluating the efficacy and safety of the venetoclax + rituximab (VR) regimen in patients with relapsed chronic lymphocytic leukemia in Polish clinical practice

Adult with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL)
Uniwersytet Medyczny W Lublinie
36 participants planned
Poland
2025-524795-35-00 on CTIS ↗
Phase III Therapeutics Authorised 26/06/2026

Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) – a randomized, prospective, multicenter, open-label, controlled phase III trial

Patients after the first year following liver transplantation
Medizinische Hochschule Hannover
150 participants planned
Germany
2025-524312-11-00 on CTIS ↗
Phase IV Hemic and Lymphatic Diseases Authorised 25/06/2026

A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol

Haematological diseases; any disorder that primarily affects the blood, bone marrow, the lymphatic system and/or blood-forming organs.
Region Hovedstaden
200 participants planned
Denmark
2026-525658-13-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 25/06/2026

Evaluating the effect of inhaled levodopa (Inbrija®) for early morning off in Parkinson’s disease

parkinson's disease
Region Hovedstaden
22 participants planned
Denmark
2026-526465-18-00 on CTIS ↗
Phase I Immune system processes Authorised 25/06/2026

A Phase 1 Study of LBL-051 in Patients with Refractory Autoimmune Disease

B-cell–mediated autoimmune diseases
Oblenio Bio Inc.
57 participants planned
Germany · Romania
2026-525621-20-00 on CTIS ↗
Phase I Immune System Diseases Authorised 25/06/2026

Phase 1 Single Dose Study of JADE201 in Participants with Rheumatoid Arthritis

Rheumatoid Arthritis
Jade Biosciences Inc.
24 participants planned
Romania · Bulgaria · Germany
2025-524746-96-00 on CTIS ↗
Phase II Eye Diseases Authorised 25/06/2026

An open-label multiple dose safety, tolerability and exploratory efficacy clinical trial of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration

Geographic atrophy secondary to age-related macular degeneration
PulseSight Therapeutics
24 participants planned
France
2025-525008-12-00 on CTIS ↗
Phase IV Diagnosis Authorised 25/06/2026

ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment

prostate cancer
Centre Hospitalier Universitaire De Toulouse
30 participants planned
France
2026-525181-22-00 on CTIS ↗
Phase III Immune System Diseases Authorised 24/06/2026

A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS

Multiple Sclerosis
F. Hoffmann-La Roche AG
54 participants planned
Spain · France · Poland · Italy
2025-523726-40-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 24/06/2026

Morphine for resting breathlessness in severe illness and palliative care (MORE-B): a randomized clinical trial

Serious, chronic, life-limiting disease
Region Skane
40 participants planned
Sweden
2026-525838-32-00 on CTIS ↗
Phase III Mental Disorders Authorised 24/06/2026

Women victims of violences : PTSD treatment by traumatic memory reactivation under the influence of propranolol (VIOFEM)

Post-traumatic stress disorder (PTSD)
Centre Hospitalier Universitaire De Toulouse
76 participants planned
France
2025-523107-30-01 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 24/06/2026

A single and multiple dose trial assessing safety, tolerability, pharmacokinetics and pharmacodynamics of ZP6590

Weight management
Zealand Pharma A/S
88 participants planned
Germany
2026-525978-19-00 on CTIS ↗
Phase I Anesthesia and Analgesia Authorised 24/06/2026

Systemic Bioavailability and Bioequivalence of Topical Diclofenac Fysioline 23.2 mg/g gel compared with Diclofenac Diethylamine - Voltaren Forte 2.32% gel

Bioequivalence, musculoskeletal pain pain
Fysioline Oy
34 participants planned
Finland
2026-526434-21-00 on CTIS ↗
Phase I Immune System Diseases Authorised 24/06/2026

THERIPEX - A phase I/II open label non-randomized study, monocentric, single-arm, evaluating Safety and Efficacy of induced T-CD4 Treg by LV vector transduction expressing the FoxP3 cDNA in patients with IPEX syndrom

IPEX syndrome is a primary immunodeficiency caused by hemizygous mutations in the gene FOXP3, which encodes an essential transcription factor required to maintain immunological tolerance by thymus-derived regulatory T (Treg) cells., Patients affected by IPEX syndrome, proven by molecular diagnosis, with any active autoimmune complications or controlled under immunosuppressive therapy can be enrolled in this trial.
Assistance Publique Hopitaux De Paris
5 participants planned
France
2025-523305-15-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 23/06/2026

ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis

liver cirrhosis
Amsterdam UMC Stichting
634 participants planned
Netherlands
2026-526167-38-00 on CTIS ↗
Phase IV Female Urogenital Diseases and Pregnancy Complications Authorised 23/06/2026

The impact of ovarian stimulation with hMG on embryo quality in advanced age women. A randomized controlled trial

infertility
Santiago Dexeus Font Fundacio Privada
240 participants planned
Spain
2025-524761-25-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 23/06/2026

A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).

Non-cystic fibrosis bronchiectasis
Sanofi-Aventis Recherche & Developpement
41 participants planned
Poland · Spain · France · Netherlands · Germany
2025-523403-29-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 23/06/2026

Multicenter Interventional Study Somatrogon Impact on Outcomes in Naive Small for Gestational Age or Idiopathic Short Stature paediatric patients compared with daily growth hormone

Small for gestational age (SGA) and idiopathic short stature (ISS)
Schneider Children's Medical Center Of Israel
95 participants planned
Greece · Poland · France · Czechia
2025-523832-38-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 23/06/2026

USEFULNESS OF HIGH-FLOW OXYGEN THERAPY TO IMPROVE THE SAFETY OF PATIENTS AT HIGH RISK OF HYPOXEMIA UNDERGOING DIGESTIVE ENDOSCOPY UNDER DEEP SEDATION: A RANDOMIZED MULTICENTER COMPARATIVE STUDY. THE ENDOALF-TRIAL.

Hypoxemic episodes in patients undergoing gastroscopy, colonoscopy, or oral endoscopic ultrasound under deep sedation with oxygen therapy administration.
Hospital Universitario Rio Hortega
326 participants planned
Spain
2026-525766-21-01 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 23/06/2026

ECSIP : Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial

patients with influenza-induced acute hypoxemic respiratory failure
Centre Hospital Region Metz Thionville
544 participants planned
France
2025-524976-40-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 23/06/2026

An Open-Label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Relapsing-Remitting Multiple Sclerosis (RRMS)
F. Hoffmann-La Roche AG
9 participants planned
Poland · Germany · France
2025-524164-37-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 23/06/2026

A Phase IIb, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50).

Heriditary spastic paraplegia (SPG50)
Rigshospitalet, Elpida Therapeutics SPC
2 participants planned
Denmark
2025-524481-15-00 on CTIS ↗
Phase IV Musculoskeletal Diseases Authorised 23/06/2026

Treatment strategies for juvenile idiopathic arthritis patients with sustained inactive disease: A phase 4, multicentre, randomised trial comparing maintenance versus tapered TNF alpha inhibitor monotherapy - the Treat-JIA trial

Juvenil Idiopatic Arthritis
Oslo Universitetssykehus HF
90 participants planned
Norway
2026-525611-13-00 on CTIS ↗
Phase III Male Urogenital Diseases Authorised 23/06/2026

SERENDIPITY: phase III multicentric randomized study assessing the reduction of chronic prostate inflammation with Permixon®

Benign prostatic hypertrophy
Azienda Ospedaliero Universitaria Careggi, University Of Florence
410 participants planned
Italy
2025-525123-27-00 on CTIS ↗
Phase III Neoplasms Authorised 23/06/2026

A Prospective, Randomized, Controlled, Multinational, Phase 2/3, Open-Label Trial to Evaluate the Efficacy and Safety of SIL204-SL Administered as an Integrated Therapeutic Regimen in Combination with Chemotherapy vs. Chemotherapy Treatment Alone in Participants with Locally Advanced Pancreatic Cancer

Non-Resectable Locally Advanced Pancreatic Cancer (LAPC)
Silexion Therapeutics Ltd.
10 participants planned
Germany
2025-525157-39-00 on CTIS ↗
Phase II Neoplasms Authorised 23/06/2026

Efficacy of asciminib in chronic phase CML patients with T315l mutations

Chronic Myeloid Leukemia
Friedrich-Schiller-Universitaet Jena
50 participants planned
Germany
2025-523491-23-00 on CTIS ↗
Phase III Immune System Diseases Authorised 22/06/2026

A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Hereditary Angioedema
Adarx Pharmaceuticals Inc.
45 participants planned
Poland · Italy · Hungary · France · Austria · Czechia · Belgium · Spain · Bulgaria · Germany · Croatia
2025-521353-16-00 on CTIS ↗
Phase I/II Neoplasms Authorised 22/06/2026

Exploratory study of the performance of dynamic PET-CT acquisition to predict 6-month morphological response in patients with hepatocellular carcinoma treated with selective internal radiotherapy

HCC – Hepatocellular Carcinoma
Centr Georges Francois Leclerc
30 participants planned
France
2026-526324-48-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 22/06/2026

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Non-active Secondary Progressive Multiple Sclerosis (SPMS)
Zenas Biopharma (USA) LLC
486 participants planned
Germany · Bulgaria · Netherlands · Sweden · Portugal · Croatia · Italy · Austria · Spain · Poland · France · Denmark · Hungary · Romania · Estonia · Slovakia · Belgium · Czechia · Norway · Lithuania · Greece
2025-524322-18-00 on CTIS ↗
Phase II Neoplasms Authorised 22/06/2026

An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).

Muscle-invasive Bladder Cancer
Astellas Pharma Global Development Inc.
88 participants planned
Germany · France · Poland · Italy · Spain
2025-524488-18-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 22/06/2026

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis

Colitis ulcerative
Merck Sharp & Dohme LLC
44 participants planned
Italy · Greece · Netherlands · Poland · Germany · France
2025-523479-49-00 on CTIS ↗
Phase II Neoplasms Authorised 22/06/2026

Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Verastem Inc.
4 participants planned
France
2025-524713-88-00 on CTIS ↗
Phase I/II Musculoskeletal Diseases Authorised 22/06/2026

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Single Ascending Doses of TRCN-1023 Administered by Intrathecal Injections to Adult People Living with Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis
Trace Neuroscience Inc.
20 participants planned
Germany · Netherlands
2025-523111-11-00 on CTIS ↗
Phase IV Musculoskeletal Diseases Authorised 22/06/2026

Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program

Metachromatic leukodystrophy
Orchard Therapeutics (Europe) Limited
29 participants planned
Netherlands · Germany · Italy · Sweden · France
2025-522275-28-00 on CTIS ↗
Phase I Neoplasms Authorised 22/06/2026

Safety and Tolerability of REGN17235 in Adult Participants with Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome with SF3B1 Mutation

Clonal Cytopenia of Undetermined Significance with SF3B1 mutation, Low-Risk Myelodysplastic Syndrome with SF3B1 mutation
Regeneron Pharmaceuticals Inc.
15 participants planned
Belgium
2026-525464-18-00 on CTIS ↗
Phase II Mental Disorders Authorised 22/06/2026

Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study

Posttraumatic stress disorder
ARQ National Psychotrauma Centrum
12 participants planned
Netherlands
2025-521488-11-00 on CTIS ↗
Phase II Bacterial Infections and Mycoses Authorised 22/06/2026

Supplementary Oxygen Therapy after Limb Debridement and Reconstruction Surgery in Infected Extremity Fractures (SOLDIER): a pilot, non-blinded, randomized controlled trial

Fracture-Related Infection
Amsterdam UMC Stichting
50 participants planned
Netherlands
2026-525871-24-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 22/06/2026

A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)

Narcolepsy with Cataplexy (NT1)
Takeda Development Center Americas Inc.
69 participants planned
Spain · Italy · France
2025-522587-33-00 on CTIS ↗
Phase II Eye Diseases Authorised 22/06/2026

Pain Relief at Screening for Retinopathy of Prematurity - The PROPER study

Retinopathy of prematurity
St. Olavs Hospital HF
33 participants planned
Norway
2023-507975-23-01 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 22/06/2026

Effects of bempedoic acid/ezetimibe/high-intensity statin on plaque regression and stabilisation of coronary atherosclerosis among patients without cardiovascular events

Coronary atherosclerosis
Daiichi Sankyo Europe GmbH
103 participants planned
Italy · Spain · Germany
2025-524625-41-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 22/06/2026

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)

Osteogenesis Imperfecta
Angitia Inc. Ltd.
40 participants planned
Netherlands · France · Denmark
2025-522951-24-00 on CTIS ↗
Phase I Neoplasms Authorised 22/06/2026

Pharmacokinetics, safety, and immunogenicity comparison of Bmab1700 and Opdivo® as adjuvant monotherapy in patients with melanoma

Stage IIB/C, Stage III, or Stage IV Melanoma
Biocon Biologics UK PLC
43 participants planned
Spain · Romania
2025-525158-20-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 22/06/2026

A Phase 2, Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of LTG-321 in Patients with Osteoarthritis of the Knee

Osteoarthritis of the knee
Latigo Biotherapeutics Inc.
180 participants planned
Denmark
2026-525966-22-00 on CTIS ↗
Phase III Immune System Diseases Authorised 19/06/2026

A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)

Systemic Sclerosis
Celgene Corp.
37 participants planned
Spain · Germany · France · Italy · Belgium
2025-524337-11-00 on CTIS ↗
Phase I Immune System Diseases Authorised 19/06/2026

A Phase 1 first-in-human study to evaluate SAR448272 in adult participants

healthy volunteers, immunological diseases
Sanofi-Aventis Recherche & Developpement
147 participants planned
Germany
2026-526014-87-00 on CTIS ↗
Phase IV Nutritional and Metabolic Diseases Authorised 19/06/2026

Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i

Type 2 diabetes
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
60 participants planned
Spain
2025-523374-17-03 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 19/06/2026

Epcoritamab in Relapsed/Refractory Marginalzone Lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (EPOS-1)

Marginal Zone Lymphoma
Universitaetsklinikum Ulm AöR
53 participants planned
Germany
2025-524879-23-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 19/06/2026

Tacrolimus as prophylaxis of post-ERCP pancreatitis: a DPSG (Dutch Pancreatitis Study Group) multicenter, double-blind, randomized, placebo-controlled study.

Post-ERCP Pancreatitis
Amsterdam UMC Stichting
520 participants planned
Netherlands
2025-522900-26-00 on CTIS ↗
Phase I Not possible to specify Authorised 19/06/2026

A study to see how safe a new medicine (NNC6022-0004) is in healthy people and people living with obesity

Cardiometabolic
Novo Nordisk A/S
128 participants planned
Netherlands
2026-525179-26-00 on CTIS ↗
Phase I/II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 18/06/2026

Long-term Follow-up (LTFU) Study of Participants in any iECURE Protocol Using an Investigational Product

Ornithine Transcarbamylase Deficiency (OTC)
Iecure Inc.
3 participants planned
Spain · France
2024-514190-21-00 on CTIS ↗
Phase I Respiratory Tract Diseases Authorised 18/06/2026

A first study in healthy volunteers to examine the safety and tolerability of convalescent plasma given through the nose,  as well as the duration of its presence in the nose

Healthy volunteers
Rode Kruis-Vlaanderen
104 participants planned
Belgium
2025-525085-29-00 on CTIS ↗
Phase I Skin and Connective Tissue Diseases Authorised 18/06/2026

A Study to Learn How Different Amounts of the Study Intervention Called PF-07832837 are Tolerated and Act in the Body in Healthy Adults and Patients

Atopic Dermatitis
Pfizer Inc.
19 participants planned
Poland
2025-524150-34-00 on CTIS ↗
Phase I Male Urogenital Diseases Authorised 18/06/2026

A study to check whether adding RUTI® to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the body’s defenses, with participants randomly receiving RUTI® or a look-alike treatment.

High-risk non-muscle invasive bladder cancer (NMIBC)
Laboratorio Reig Jofre S.A.
44 participants planned
Spain
2026-525897-20-00 on CTIS ↗
Phase III Neoplasms Authorised 18/06/2026

Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO

Advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma
Fondazione GONO G.I.
212 participants planned
Spain · Germany · Italy
2025-524048-36-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 18/06/2026

A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)

PARKINSON’S DISEASE
Universitaetsklinikum Tuebingen AöR
110 participants planned
Spain · Germany · Italy · Sweden · France · Luxembourg
2024-513496-40-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 17/06/2026

A multicentre, randomized, double-blind, placebo-controlled phase II/III trial investigating the efficacy of anti-FcRn targeting with efgartigimod as a first-line add-on therapy to IVMP in moderate-to-severe attacks of demyelinating diseases of the central nervous system

Demyelinating diseases
Medizinische Hochschule Hannover
116 participants planned
Germany · Austria
2025-523654-13-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 17/06/2026

Preventive effect of 5% lidocaine patch on the development of neuropathic pain following an osteoporotic vertebral fracture: A proof-of-concept, controlled, randomized trial

Osteoporotic Fracture
University Hospital Of Clermont-Ferrand
30 participants planned
France
2025-524889-25-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 17/06/2026

STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial

ulcerative colitis
Centre Hospitalier Regional De Marseille
224 participants planned
France
2026-525643-32-00 on CTIS ↗
Phase I Neoplasms Authorised 17/06/2026

A Study to Learn About How Different Forms of Study Medicine Prifetrastat are Taken Up Into the Blood in Healthy Adults

Locally advanced or metastatic ER+/HER2- breast cancer
Pfizer Inc.
32 participants planned
Belgium
2026-526038-26-00 on CTIS ↗
Phase I Neoplasms Authorised 17/06/2026

Phase 1/1b Study of RNDO-564 in Participants with Advanced Urothelial Cancer

Other Solid Tumors Associated with Nectin-4 Expression, Relapsed/Refractory Locally Advanced or Metastatic Urothelial Cancer
Rondo Therapeutics Inc.
34 participants planned
Spain
2025-524687-38-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 17/06/2026

A phase 1 first-in-human study of a phenylalanine-binding polymer (phelimin) in healthy volunteers and adult, classical PKU patients

Phenylketonuria
Mipsalus ApS
7 participants planned
Denmark
2024-519121-38-01 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 17/06/2026

IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis

Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis
Bristol-Myers Squibb Services Unlimited Company
318 participants planned
Finland · Portugal · Hungary · Ireland · Poland · Greece · France · Belgium · Denmark · Italy · Spain · Netherlands · Austria · Germany
2025-522373-10-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 17/06/2026

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period

Systemic sclerosis
Galderma S.A.
56 participants planned
Poland · Italy · Bulgaria · France · Greece · Spain · Croatia
2025-522294-11-00 on CTIS ↗
Phase I Skin and Connective Tissue Diseases Authorised 16/06/2026

A First‑in‑Human Phase 1 Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants

Healthy volunteers
Arcus Biosciences Inc.
130 participants planned
Netherlands
2026-526279-52-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 16/06/2026

RADICAL-IO: thRee cycles of immunotherApy without raDical therapy In mediCALly InOperable stage I non-small cell lung cancer

Stage I non-small cell lung cancer
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
30 participants planned
Netherlands
2025-524305-32-00 on CTIS ↗
Phase I Neoplasms Authorised 16/06/2026

Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer

Solid Tumors
Theras Inc.
2999997 participants planned
Spain · Italy · France
2025-524690-16-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 16/06/2026

A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

Duchenne Muscular Dystrophy
Entrada Therapeutics Inc.
56 participants planned
Belgium · Italy · Netherlands · Spain
2025-525124-10-00 on CTIS ↗
Phase I Neoplasms Authorised 16/06/2026

A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Hematological malignancies, Advanced solid tumors
Incyte Corp.
150 participants planned
Italy · Belgium · Denmark
2025-523130-11-00 on CTIS ↗
Phase III Neoplasms Authorised 16/06/2026

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer Expressing Claudin18.2
AstraZeneca AB
516 participants planned
France · Italy · Spain · Hungary · Poland · Belgium · Germany · Netherlands
2024-519787-40-00 on CTIS ↗
Phase I/II Neoplasms Authorised 16/06/2026

A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC)

Metastatic Prostate Cancer
AstraZeneca AB
45 participants planned
Belgium · Spain · Poland · Italy · Netherlands
2025-520626-37-00 on CTIS ↗
Phase III Neoplasms Authorised 16/06/2026

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

Stage I NSCLC
Merck Sharp & Dohme LLC
283 participants planned
Greece · Poland · Italy · Hungary · Germany · Netherlands · France · Spain
2025-522643-18-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 16/06/2026

A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease

Ulcerative colitis (Inflammatory Bowel Disease)
Spyre Therapeutics Inc.
228 participants planned
Croatia · Poland · Austria · Czechia · Italy · Slovakia · Bulgaria · Greece · Belgium · Spain · Hungary · Germany · Lithuania · France · Romania
2025-524640-35-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 15/06/2026

Achieve - ACetazolamide in patients with Heart failure, to decrease weight and relIEVE symptoms

Heart failure
Centre Hospitalier Universitaire De Montpellier
1050 participants planned
France
2025-524344-35-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 15/06/2026

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica

Musculoskeletal diseases
Sanofi-Aventis Recherche & Developpement
177 participants planned
France · Netherlands · Germany · Czechia · Belgium · Austria · Hungary · Greece · Spain
2024-511296-15-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 15/06/2026

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)

Limb Girdle Muscular Dystrophy (LGMD) Type 2I
ML Bio Solutions Inc.
35 participants planned
Germany · Denmark · Netherlands · Italy · Norway
2025-524371-23-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 15/06/2026

A single arm single center exploratory observational phase II study, aimed to detect long term changes in volume of port-wine macrocheilia and color of port-wine stain in patients undergoing surgery and laser therapy during sirolimus treatment. Quality of life and efficacy and safety of sirolimus will be assessed.

Vascular malfomation
Oslo University Hospital HF
20 participants planned
Norway
2024-511937-37-01 on CTIS ↗
Phase II Neoplasms Authorised 15/06/2026

A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Participants with RRMM, who Received 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy

Multiple myeloma (RRMM)
Odense University Hospital
50 participants planned
Finland · Denmark · Estonia · Norway
2025-522114-23-00 on CTIS ↗
Phase IV Immune System Diseases Authorised 15/06/2026

Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)

C3 Glomerulopathy (C3G), Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Swedish Orphan Biovitrum AB (publ)
82 participants planned
France · Italy · Spain · Germany · Belgium
2025-524487-37-00 on CTIS ↗
Phase II Diagnosis Authorised 13/06/2026

Exploratory study evaluating the relevance of [68Ga]Ga-FAPI-46 for staging and identifying progressing patients with transthyretin cardiac amyloidosis

Transthyretin cardiac amyloidosis
Centre Hospitalier Universitaire De Nantes
40 participants planned
France
2025-523616-36-00 on CTIS ↗
Phase III Neoplasms Authorised 12/06/2026

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)

Locally advanced, unresected (unresectable or medically inoperable or refuse surgery) Stage II-III NSCLC with KRAS G12C mutation​
Merck Sharp & Dohme LLC
88 participants planned
Italy · Netherlands · France · Germany · Spain · Poland · Greece
2025-522038-29-00 on CTIS ↗
Phase I Not possible to specify Authorised 12/06/2026

A Safety Study to Test a New Medicine (ANT3310) Alone and When Taken with an Antibiotic (Meropenem) in Healthy Adult Participants.

Not applicable for phase I study
Antabio
40 participants planned
France
2026-526411-11-00 on CTIS ↗
Phase III Neoplasms Authorised 12/06/2026

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

​Relapsed/refractory B-cell Acute Lymphoblastic Leukemia​
Merck Sharp & Dohme LLC
109 participants planned
Greece · Netherlands · Sweden · France · Italy · Spain · Denmark
2025-522267-15-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 12/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Glaxosmithkline Research & Development Limited
210 participants planned
Greece · Germany · Belgium · Netherlands · Poland · Italy · France · Spain · Bulgaria · Austria
2025-523674-16-00 on CTIS ↗
Phase IV Musculoskeletal Diseases Authorised 12/06/2026

BEAT Fatigue – Benefit of Elevated Administration of Thiamine for Fatigue in Rheumatoid Arthritis: A randomized, double-blind, placebo-controlled trial

Fatigue in rheumatoid arthritis patients
Odense University Hospital
150 participants planned
Denmark
2024-519268-41-00 on CTIS ↗
Phase I Reproductive and Urinary Physiological Phenomena Authorised 12/06/2026

Study to assess the relative bioavailability of Neludolat versus YAZ in healthy female subjects.

Healthy subjects
Pevisal Group Farmaceutici S.r.l.
24 participants planned
Czechia
2025-524871-22-00 on CTIS ↗
Phase II Neoplasms Authorised 12/06/2026

A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2

patients with unrestectable hepatocellular carcinoma (SLIDE-HCC)
IRCCS Istituto Nazionale Tumori Fondazione Pascale
56 participants planned
Italy
2025-521608-23-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 11/06/2026

J6Z-MC-IIBD - A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease J6Z-MC-CD01 - A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared with Mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease

J6Z-MC-IIBD - Colitis, Ulcerative Crohn Disease J6Z-MC-CD01 - Crohn Disease
Eli Lilly & Co.
37 participants planned
Italy · Germany · Hungary · Poland · Belgium
2025-524112-11-00 on CTIS ↗
Phase I/II Immune System Diseases Authorised 11/06/2026

Phase I-IIa, national, multicenter, clinical trial to evaluate the safety and preliminary efficacy of CAR-T CD19 therapy in patients with refractory lupus nephritis.

Refractory Lupus Nephritis
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz
10 participants planned
Spain
2025-522449-23-00 on CTIS ↗
Phase III Otorhinolaryngologic Diseases Authorised 11/06/2026

Evaluation of the Non-Inferiority of Topical Chloramphenicol Versus Topical Ciprofloxacin in the Resolution of Otorrhea in Adults With Chronic Suppurative Otitis Media (CSOM) – Protocol OMCOS

chronic suppurative otitis media (CSOM)
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre
88 participants planned
Spain
2026-525540-15-00 on CTIS ↗
Phase II Neoplasms Authorised 11/06/2026

A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

HER2-negative, unresectable, recurrent, and/or metastatic gastric, GEJ, and esophageal adenocarcinomas
Gilead Sciences Inc.
45 participants planned
Spain · France
2025-524095-27-00 on CTIS ↗
No trials match your search.

Browse by country

Spain · 219 Germany · 207 France · 205 Italy · 156 Poland · 117 Netherlands · 106 Belgium · 94 Denmark · 80 Greece · 56 Czechia · 55 Hungary · 53 Sweden · 52 Austria · 45 Bulgaria · 40 Romania · 38 Portugal · 35 Norway · 35 Finland · 24 Slovakia · 20 Ireland · 16 Lithuania · 11 Croatia · 9 Latvia · 6 Estonia · 6
Cite this page

Priya Life Science (2026). EU Clinical Trials Tracker. Available at: https://priyalifescience.com/clinical-trials-europe (Accessed: 14 September 2026).

Embed this data ↗

Source: Clinical Trials Information System (CTIS), European Medicines Agency - trials authorised under the EU Clinical Trials Regulation (Regulation 536/2014), showing the most recent EU authorisation decisions, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See our Ireland Clinical Trials Tracker. For approved medicines, see the EMA Approvals Tracker. See who's running these trials in our Company Directory, or compare pay across these markets in the EU Salary Guide.